



US 20100015113A1

(19) **United States**

(12) **Patent Application Publication**  
**Restifo et al.**

(10) **Pub. No.: US 2010/0015113 A1**  
(43) **Pub. Date: Jan. 21, 2010**

(54) **GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE**

(75) Inventors: **Nicholas P. Restifo**, Chevy Chase, MD (US); **Lydie Cassard**, Bethesda, MD (US); **Zhiya Yu**, Rockville, MD (US); **Steven A. Rosenberg**, Potomac, MD (US)

Correspondence Address:  
**LEYDIG, VOIT & MAYER, LTD.**  
**TWO PRUDENTIAL PLAZA, SUITE 4900, 180**  
**NORTH STETSON AVENUE**  
**CHICAGO, IL 60601-6731 (US)**

(73) Assignee: **The United States of America, as represented by the Secretary, Dept. of Health and Human Services**, Bethesda, MD (US)

(21) Appl. No.: **12/522,321**

(22) PCT Filed: **Jan. 11, 2008**

(86) PCT No.: **PCT/US08/50841**

§ 371 (c)(1),  
(2), (4) Date: **Aug. 10, 2009**

**Related U.S. Application Data**

(60) Provisional application No. 60/884,732, filed on Jan. 12, 2007, provisional application No. 60/885,724, filed on Jan. 19, 2007.

**Publication Classification**

(51) **Int. Cl.**  
*A61K 35/12* (2006.01)  
*C12N 5/08* (2006.01)  
*C07K 14/725* (2006.01)  
*C07K 16/18* (2006.01)  
*C07H 21/04* (2006.01)  
*C12N 15/63* (2006.01)  
*G01N 33/53* (2006.01)  
*A61P 35/04* (2006.01)  
(52) **U.S. Cl.** ..... **424/93.71**; 435/372.3; 530/350;  
530/387.3; 536/23.5; 435/320.1; 530/387.9;  
435/7.1

(57) **ABSTRACT**

The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.

FIG. 1




FIG. 2




FIG. 3





FIG. 4



## FIG. 5A

Sp(0.01)A TCR  $\alpha$  chain cDNA

```
1 atgaaatcct tgagtgttc cctagtggtc ctgtggctcc agttaaactg ggtgaacagc
61 cagcagaagg tgcagcagag cccagaatcc ctcattgtcc cagagggagc catgacctct
121 ctcaactgca ctttcagcga cagtgtttct cagtatthttg catgggtacag acagcattct
181 gggaaaagccc ccaaggcact gatgtccatc ttctccaatg gtgaaaaaga agaaggcaga
241 ttcacaattc acctcaataa agccagtctg catttctcgc tacacatcag agactcccag
301 ccagtgact ctgctctcta cctctgtgca gccataaact atgcccaggg attaaccttc
361 ggtcctggca ccagagtatc tgtgtttccc tacatccaga acccagaacc tgctgtgtac
421 cagttaaaag atcctcggtc tcaggacagc accctctgcc tgttcaccga ctttgactcc
481 caaatcaatg tgccgaaaac catggaatct ggaacgttca tcaactgaaa aactgtgctg
541 gacatgaaag ctatggatto caagagcaat ggggccattg cctggagcaa ccagacaagc
601 ttcacctgcc aagatatctt caaagagacc aacgccacct accccagttc agacgttccc
661 tgtgatgcca cgttgactga gaaaagcttt gaaacagata tgaacctaaa ctttcaaaac
721 ctgtcagtta tgggactccg aatcctcctg ctgaaagtag cgggatttaa cctgctcatg
781 acgctgagcc tgtggtccag ttga
```

Sp(0.01)A TCR  $\alpha$  chain protein (translated from cDNA)

```
MKSLSVSLVVLWLQLNWNVSQQKVVQSPESLIVPEGAMTSLNCTFSDSASQYFAWYRQHSGKAPKALMSIFSNGEKEE
GRFTIHLNKASLHFSLHIRDSQPSDSALYLCAANNYAQGLTFGLGTRVSVFPYIQNPEPAVYQLKDPRSQDSTLCLFT
DFDSQINVPKIMESGTFITDKIVLDMKAMDSSKNGAIAWSNQTISFTQDIFKETNATYPSDVP CDATLLEKSFETDM
NLNFQNL SVMGLRILLKLVAGFNLLMTRLRWSS
```

## FIG. 5B


Sp(0.01)A TCR  $\beta$  chain cDNA

```
1 atgggctcca gactcttctt tgtggttttg attctcctgt gtgcaaaaca catggaggct
61 gcagtcaccc aaagtccaag aagcaagggt gcagtaacag gaggaaaagg gacattgagc
121 tgtcaccaga ctaataacca tgactatatg tactgggtatc ggcaggacac ggggcatggg
181 ctgaggctga tccattactc atatgtcgct gacagcacgg agaaggaga tatccctgat
241 gggtaacaag cctccagacc aagccaagag aatttctctc tcattctgga gttggcttcc
301 ctttctcaga cagctgtata tttctgtgcc agcagccctg gggggggggg ggaacagtac
361 ttcgggtccg gcaccaggct cacggtttta gaggatctga gaaatgtgac tccaccaag
421 gtctccttgt ttgagccatc aaaagcagag attgcaaaaca aacgaaaggc taccctcgtg
481 tgcttgcca ggggcttctt cctgaccac gtggagctga gctgggtggg gaatggcaag
541 gaggccaca gtgggtcag cacggaccct caggcctaca aggagagcaa ttatagctac
601 tgctgagca gccgcctgag ggtctctgct accttctggc acaatcctcg aaaccacttc
661 cgctgccaag tgcagttcca tgggctttca gaggaggaca agtggccaga gggctcacc
721 aaacctgtca cacagaacat cagtgcagag gcctggggcc gagcagactg tgggattacc
781 tcagcatcct atcaacaagg ggtcttgtct gccaccatcc tctatgagat cctgctaggg
841 aaagccacc tgtatgctgt gcttgtcagt acactggtgg tgatggctat ggtcaaaaga
901 aagaattcat ga
```

Sp(0.01)A TCR  $\beta$  chain protein (translated from cDNA)

```
MGSRLFFVVLILLCAKHMEAAVTQSPRSKVAVTGGKVTLSCHQINNHDYMYWYRQDTGHGLRLIHYSYVADSTEKGDI
PDGYKASRPSQENFSLILELASLSQTAVYFCASSPGGGGEQYFGPGRRLTVLEDLRNVTPPKVSLFEP SKAEIANKRK
ATLVCLARGFFPDHVELSWVNGKEVHSGVSTDPQAYKBSNYSYCLSSRLRVSATFWHNP RNHFRCQVQFHGLSEEDK
WPEGSPKPVIQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVMMAMVKRKN
```

FIG. 6






FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B







FIG. 9C



## FIG. 10A

T2(1) B  $\alpha$  chain

ATGATGAAGACATCCCTTCACACTGTATTCCCTATTCTTGTGGCTATGGATGGACTGGGAGAGCCATGGAGA  
GAAGGTCGAGCAACATGAGTCTACACTGAGTGTTCGAGAGGGAGACAGCGCTGTCATCAACTGCCTTACA  
CAGATACTGCTTCATCATACTTCCTTGGTACAAGCAAGAAGCTGGAAAGAGTCTCCACTTTGTGATAGAC  
ATTTCGTTCAAATGTGGACAGAAAACAGAGCCAAAGACTTATAGTTTTGTTGGATAAGAAAGCCAAACGATT  
CTCCCTGCACATCACAGCCACACAGCCTGAAGATTCAGCCATCTACTTCTGTGCAGCAAGCTCGGATAGCA  
ACTATCAGTTGATCTGGGGCTCTGGGACCAAGCTAATTATAAAGCCAGACATCCAGAACCAGAACCTGCT  
GTGTACCAGTTAAAAGATCCTCGGTCTCAGGACAGCACCCCTCTGCCTGTTCAACCGACTTTGACTCCCAAAT  
CAATGTGCCGAAAACCATGGAATCTGGAACGTTTCATCACTGACAAAACCTGTGCTGGACATGAAAGCTATGG  
ATTCCAAGAGCAATGGGGCCATTGCCTGGAGCAACCAGACAAGCTTCACCTGCCAAGATATCTTCAAAGAG  
ACCAACGCCACCTACCCAGTTTCAGACGTTCCCTGTGATGCCACGTTGACTGAGAAAAGCTTTGAAACAGA  
TATGAACCTAAACTTTCAAACCTGTCAGTTATGGGACTCCGAATCCTCCTGCTGAAAGTAGCCGGATTTA  
ACCTGCTCATGACGCTGAGGCTGTGGTCCAGTTGA

T2(1) B  $\beta$  chain

ATGTCTAACACTGCCTTCCTTGACCCCGCCTGGAACACCACCCTGCTATCTTGGGTTGCTCTCTTTCTCCT  
GGGAACAAGTTCAGCAAATTCGGGGTTGTCCAGTCTCCAAGATACATAATCAAAGGAAAGGGAGAAAGGT  
CCATTCTAAAATGTATTCCCATCTCTGGACATCTCTCTGTGGCCTGGTATCAACAGACTCAGGGGCAGGAA  
CTAAAGTTCTTCATTCAGCATTATGATAAAATGGAGAGAGATAAAGGAAACCTGCCAGCAGATTCTCAGT  
CCAACAGTTTGATGACTATCACTCTGAGATGAACATGAGTGCCTTGGAGCTAGAGGACTCTGCCGTGTA  
TCTGTGCCAGCTCTCTTTCTGGGGCGAATATGCTGAGCAGTTCTTCGGACCAGGGACAGACTCACCGTC  
CTAGAGGATCTGAGAAATGTGACTCCACCAAGGTCCTTGTGTTGAGCCATCAAAGCAGAGATTGCAAA  
CAAACAAAAGGCTACCCCTCGTGTGCTTGCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGGTGGG  
TGAATGGCAAGGAGTCCACAGTGGGGTCAGCACGGACCCCTCAGGCTACAAAGGAGCAATTATAGCTAC  
TGCTGAGCAGCCGCTGAGGGTCTCTGCTACCTTCTGGCACAATCCTCGAAAACACTTCCGCTGCCAAGT  
GCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCCAAACCTGTCACACAGAACATCA  
GTGCAGAGGCTGGGGCCGAGCAGACTGTGGGATTACCTCAGCATCCTATCAACAAGGGTCTTGTCTGCC  
ACCATCCTCTATGAGATCCTGCTAGGGAAAGCCACCCGTATGCTGTGCTTGTGCTGACTGCTGGTGGT  
GGCTATGGTCAAAGAAAGAATTCATGA

## FIG. 10B

### Sp(0.1)A10 $\alpha$ chain

ATGCTCCTGGCGCTCCTCCCAGTGTGGGGATACACTTTGTCCTGAGAGATGCCAAGCTCAGTCAGTGAC  
ACAGCCCGATGCTCGCGTCACTGTCTCTGAAGGAGCCTCTCTGCAGCTGAGATGCAAGTATTCCTACTCTG  
CGACACCTTATCTGTTCTGGTATGTCCAGTACCCGCGGCAGGGGCTGCAGCTGCTCCTCAAGTACTATTCA  
GGAGACCCAGTGGTTCAAGGAGTGAACAGCTTCGAGGCTGAGTTCAGCAAGAGTAACTCTCCTTCCACCT  
GCAGAAAGCCTCTGTGCACTGGAGCGACTCGGCTGTGTACTTCTGTGCTCTGAGCCACGATAGCAACTATC  
AGTTGATCTGGGGCTCTGGGACCAAGCTAATTATAAAGCCAGACATCCAGAACCAGAACCTGCTGTGTAC  
CAGTTAAAAGATCCTCGGTCTCAGGACAGCACCTCTGCCTGTTACCGACTTTGACTCCCAAATCAATGT  
GCCGAAAACCATGGAATCTGGAACGTTTATCACTGACAAAACCTGTGCTGGACATGAAAGCTATGGATTCCA  
AGAGCAATGGGGCCATTCCTGGAGCAACCAGACAAGCTTCACCTGCCAAGATATCTTCAAAGAGACCAAC  
GCCACCTACCCAGTTCAGACGTTCCCTGTGATGCCACGTTGACTGAGAAAAGCTTTGAAACAGATATGAA  
CCTAAACTTTCAAACCTGTGAGTTATGGGACTCCGAATCCTCCTGCTGAAAAGTAGCCGGATTTAACCTGC  
TCATGACGCTGAGGCTGTGGTCCAGTTGA

### Sp(0.1)A10 $\beta$ chain

ATGCTAACACTGCCTTCCCTGACCCCGCCTGGAACACCACCCTGCTATCTTGGGTTGCTCTCTTTCTCCT  
GGGAACAAGTTCAGCAAATTCTGGGGTTGTCCAGTCTCCAAGATACATAATCAAAGGAAAGGGAGAAAGGT  
CCATTCTAAAATGTAFTCCCATCTCTGGATATCTCTCTGTGGCTGGTATCAACAGACTCAGGGGCAGGAA  
CTAAAGTTCTTCAATTCAGCATTATGATAAAATGGAGAGAGATAAAGGAAACCTGCCAGCAGATTCTCAGT  
CCAACAGTTTGATGACTATCACTCTGAGATGAACATGAGTGCCTTGGAGCTAGAGGACTCTGCCGTGACT  
TCTGTGCCAGCTCTCTCGCGGGGTTAACTATGCTGAGCAGTTCTTCGGACCAGGGACACGACTCACCGTC  
CTAGAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTFTGAGCCATCAAAGCAGAGATTGCAAA  
CAAACAAAAGGCTACCCTCGTGTGCTTGGCCAGGGGCTTCTCCCTGACCACGTGGAGCTGAGCTGGTGGG  
TGAATGGCAAGGAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTAC  
TGCTTGAGCAGCCGCTGAGGGTCTCTGCTACCTTCTGGCACAAATCCTCGAAACCACTTCCGCTGCCAAGT  
GCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCCAAACCTGTACACACAGAACATCA  
GTGCAGAGCCCTGGGGCCGAGCAGACTGTGGGATTACCTCAGCATCCTATCAACAAGGGGTCTGTCTGCC  
ACCATCCTCTATGAGATCCTGCTAGGGAAAGCCACCCTGTATGCTGTGCTTGTGAGTACACTGGTGGTGTG  
GGCTATGGTCAAAGAAAGAATTCATGA

## FIG. 10C

T2(1) C  $\alpha$  chain

ATGATGAAGACATCCCTTCACACTGTATTCCATTCCTTGTGGCTATGGATGGACTGGGAGAGCCATGGAGA  
GAAGGTCGAGCAACATGAGTCTACACTGAGTGTTCGAGAGGGAGACAGCGCTGTCATCAACTGCACTTACA  
CAGATACTGCTTCATCATACTTCCCTTGGTACAAGCAAGAAGCTGGAAAGAGTCTCCACTTTGTGATAGAC  
ATTCGTTCAAATGTGGACAGAAAACAGAGCCAAAGACTTATAGTTTTGTGGATAAGAAAGCCAAACGATT  
CTCCCTGCACATCACAGCCACACAGCCTGAAGATTCAGCCATCTACTTCTGTGCAGCAAGCTCGGATAGCA  
ACTATCAGTTGATCTGGGGCTCTGGGACCAAGCTAATTATAAAGCCAGACATCCAGAACCAGAACCTGCT  
GTGTACCAGTTAAAAGATCCTCGGTCTCAGGACAGCACCCTCTGCCTGTTACCGACTTTGACTCCCAAAT  
CAATGTGCCGAAAACCATGGAATCTGGAACGTTCACTACTGACAAAACCTGTGCTGGACATGAAAGCTATGG  
ATTCCAAGAGCAATGGGGCCATTGCCTGGAGCAACCAGACAAGCTTCACCTGCCAAGATATCTTCAAAGAG  
ACCAACGCCACCTACCCAGTTTCAGACGTTCCCTGTGATGCCACGTTGACTGAGAAAAGCTTTGAAACAGA  
TATGAACCTAAACTTTCAAACCTGTGAGTTATGGGACTCCGAATCCTCCTGCTGAAAGTAGCCGGATTTA  
ACCTGCTCATGACGCTGAGGCTGTGGTCCAGTTGA

T2(1)C  $\alpha$  chain

ATGTCTAACACTGCCTTCCCTGACCCCGCCTGGAACACCACCCTGCTATCTTGGGTTGCTCTCTTTCTCCT  
GGGAACAAGTTCAGCAAATTCGGGGTTGTCCAGTCTCCAAGATACATAATCAAAGGAAAGGGAAAAAGGT  
CCATTTCAAATGTATTTCCATCTCTGGACATCTCTCTGTGGCCTGGTATCAACAGACTCAGGGGCAGGAA  
CTAAAGTTCTTCATTCAGCATTATGATAAAATGGAGAGATAAAGGAAACCTGCCAGCAGATTCTCAGT  
CCAACAGTTTGATGACTATCACTCTGAGATGAACATGAGTGCCTTGGAGCTAGAGGACTCTGCCGTGACT  
TCTGTGCCAGCTCTCTTTCTGGGGCGAATATGCTGAGCAGTTCTTCGGACCAGGGACAGACTCACCGTC  
CTAGAGGATCTGAGAAATGTGACTCCACCAAGGTCTCCTTGTGAGCCATCAAAGCAGAGATGCAAAA  
CAAACGAAAGGCTACCCCTCGTGTGCTTGGCCAGGGGCTTCTTCCCTGACCAGTGGAGCTGAGCTGGTGGG  
TGAATGGCAAGGAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTAC  
TGCTGAGCAGCTGCCTGAGGGTCTCTGCTACCTTCTGGCACAATCCTCGAAACCACTTCCGCTGCCAAGT  
GCAGTTCCATGGGCTTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCCAAACCTGTCACACAGGACATCA  
GTGCAGAGGCTGGGGCCGAGCAGACTGTGGGATTACCTCAGCATCCTATCAACAAGGGGCTTTGTCTGCC  
ACCATCCTCTACGAGATCCTGCTAGGGAAAGCCACCCTGTATGCTGTGCTTGTGCTGACTGCTGGTGGTAT  
GGCTATGGTCAAAGAAAGAATTCATGA

FIG. 11B




FIG. 11A





FIG. 12



**FIG. 13**

5' LTR, 6126-6639  
Alpha chain, 3-806  
IRES, 807-1438  
Beta chain, 1439-2350  
3' LTR, 2439-2953

```
1  ccatgtcadc cttgagtgtt tccctagtggt tcctgtggct ccagttaaac tgggtgaaca
61  gccagcagaa ggtgcagcag agcccagaat ccctcattgt cccagagggg gccatgacct
121 ctctcaactg cactttcagc gacagtgtct ctcagtattt tgcattgtac agacagcatt
181 ctgggaaagc ccccaaggca ctgatgtcca tcttctccaa tggtgaaaaa gaagaaggca
241 gattcacaaat tcacctcaat aaagccagtc tgcatttctc gctacacatc agagactccc
301 agcccagtgta ctctgtctctc tacctctgtg cagccaataa ctatgcccag ggattaacct
361 tcgggtcttgg caccagagta tctgtgtttc cctacatcca gaaccagaa cctgctgtgt
421 accagttaaa agatcctcgg tctcaggaca gcacctctg cctgttcacc gactttgact
481 cccaaatcaa tgtgcccгаа accatggaat ctggaacggt catcactgac aaaactgtgc
541 tggacatgaa agctatggat tccaagagca atggggccat tgcctggagc aaccagacaa
601 gcttcacctg ccaagatata tcaaaagaga ccaacgccac ctaccccagt tcagacgttc
661 cctgtgatgc cacgttgact gagaaaagct ttgaaacaga tatgaaacct aactttcaaa
721 acctgtcagt tatgggactc cgaatcctcc tgetgaaagt agccggattt aacctgctca
781 tgacgctgag gctgtgtgtcc agttgagcgg ccgctctaga actagtggat ctccacgtgg
841 cggctagtac tccggtattg cggtaacctt gtacgcctgt tttatactcc cttcccgtaa
901 cttagacgca caaaaaccaag tcaatagaa gggggtacaa accagtacca ccacgaacaa
961 gcaacttctgt ttccccggtg atgtcgtata gactgcttgc gtggttgaaa ggcagggatc
1021 cgttatccgc ttatgtactt cgagaagccc agtaccacct cggaaatctc gatgogttgc
1081 gctcagcact caaccaccaga gtgtagctta ggctgatgag tctggacatc cctcaccggt
1141 gacgggtggtc caggctgcgt tggcggccta cctatggcta acgccaatgg acgctagtgtg
1201 tgaacaaggt gtgaagagcc tattgagcta cataagaatc ctccggcccc tgaatggggc
1261 taatcccaac ctccggagcag gtggtcacaa accagtgatt ggcctgtcgt aacgcgcaag
1321 tccgtggcgg aaccgactac tttgggtgtc cgtgtttcct tttattttat tgtggctgct
1381 tatggtgaca atcacagatt gttatcataa agcgaattgg ataggatcaa gcttatcgat
1441 gggctccaga ctcttctttg tggttttgat tctcctgtgt gcaaaacaca tggaggtgc
1501 agtcacccaa agtccaagaa gcaaggtggc agtaacagga ggaaggtga cattgagctg
1561 tcaccagact aataaccatg actatatgta ctggtatcgg caggacacgg ggcattgggt
1621 gaggctgac cattaactcat atgtcgtgta cagcacggag aaaggagata tccctgatgg
1681 gtacaaggcc tccagaccaa gccaaagaaa tttctctctc attctggagt tggcttccct
1741 ttctcagaca gctgtatatt tctgtgccag cagccctggg gggggggggg aacagtactt
1801 cggtcocggc accaggctca cggttttaga ggatctgaga aatgtgactc cacccaaggt
1861 ctcttgtttt gagccatcaa aagcagagat tgcaaacaaa cgaagggcta ccctcgtgtg
1921 cttggccagg ggcttcttcc ctgaccagct ggagctgagc tgggtgggtg atggcaagga
1981 ggtccacagc ggggtcagca cggaccctca ggctacaag gagagcaatt atagctactg
2041 cctgagcagc cgcctgaggg tctctgctac cttctggcac aatcctcgaa accacttccg
2101 ctgccaagtg cagttccatg ggctttcaga ggaggacaag tggccagagg gctcaccocaa
2161 acctgtcaca cagaacatca gtgcagaggc ctggggccga gcagactgtg ggattacctc
2221 agcatcctat caacaagggg tcttgtctgc caccatcctc tatgagatcc tgetagggaa
2281 agccaccctg tatgctgtgc ttgtcagtac actgggtggg atggctatgg tcaaaagaaa
2341 gaattcatga taagcttcga attctgcagt cgacggtacc gcgggcccgg gatccgataa
2401 aataaaagat tttatttagt ctccagaaaa aggggggaat gaaagacccc acctgtaggt
2461 ttggcaagct agcttaagta acgccatttt gcaaggcatg gaaaatacat aactgagaat
2521 agagaagttc agatcaaggt taggaacaga gagacagcag aatatgggcc aacaggata
2581 tctgtggtaa gcagttcctg ccccggtcoa gggccaagaa cagatgggtc ccagatgccc
2641 tcccgcacctc agcagtttct agagaacat cagatgtttc cagggtgccc caaggacctg
2701 aaaatgacct tgtgccttat ttgaaactaac caatcagttc gcttctcget tctgttcgcg
2761 cgcttctgct ccccgagctc aataaaagag cccacaaccc ctcaactcggc gcgccagttcc
2821 tccgatagac tgcgtcgcgc gggtagccgt gtatccaata aacctcctt gactgtgcatc
2881 cgactgtggg tctogctggt ccttgggagg gtctcctctg agtgattgac taccgctcag
2941 cgggggtctt tcatgggtaa cagtttcttg aagttggaga acaacattct gagggtagga
3001 gtcgaatatt aagtaatcct gactcaatta gccactgttt tgaatccaca tactccaata
3061 ctctgaaat ccatcgatgg agttcattat ggacagcgca gaaagagctg gggagaattg
3121 tgaattgtt atccgctcac aattccacac aacatacgag ccggaagcat aaagtgtaaa
```


**FIG. 13 cont.**

3181 gcctggggtg cctaagtgtg gagctaactc acattaattg cgttgcgctc actgcccgtc  
3241 ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa tcggccaacg cgcggggaga  
3301 ggcggtttgc gtattgggcg ctottccgct tcctcgctca ctgactcgct gcgctcggtc  
3361 gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg taatacggtt atccacagaa  
3421 tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaacctg  
3481 aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa  
3541 aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt  
3601 ccccctggaa gctcccctgt gcgctctcct gttccgacct tgcgcttac cggatacctg  
3661 tccgcctttc tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc  
3721 agttcgggtg aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc  
3781 gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccgtaag acacgactta  
3841 tccgcaactg cagcagccac tggtaacagg attagcagag cgaggtatgt aggcgggtgct  
3901 acagagtctt tgaagtgggt gcctaactac ggctacacta gaaggacagt atttggtatc  
3961 tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa  
4021 caaaccaccg ctggtagcgg tggttttttt gtttgaagc agcagattac gcgcaaaaa  
4081 aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa  
4141 aactcacggt aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt  
4201 ttaaattaaa aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggtctgac  
4261 agttaccaat gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc  
4321 atagttgctt gactccccgt cgtgtagata actacgatac gggagggcctt accatctggc  
4381 cccagtgctg caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata  
4441 aaccagccag ccggaagggc cgagcgcaga agtggctcct caactttatc cgcctccatc  
4501 cagtctatta atgttgccg ggaagctaga gtaagtagtt cgcaggttaa tagtttgccg  
4561 aacggtgttg ccattgctac aggcacgtg gtgtcacgct cgtcgtttgg tatggttca  
4621 ttcagctccg gttcccacag atcaaggcga gttacatgat cccccatggt gtgcaaaaa  
4681 cgggttagct ccttcgggtc tccgatcgtt gtcagaagta agttggccgc agtggtatca  
4741 ctcatggtta tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt  
4801 tctgtgactg gtgagtactc aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt  
4861 tgctcttgcc cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg  
4921 ctcatcattg gaaaacggtt ttcggggcga aaactctcaa ggatcttacc gctggtgaga  
4981 tccagttcga tgaacccac tegtgcaccc aactgatctt cagcatcttt tactttcacc  
5041 agcgtttctg ggtgagcaaa aacaggaagg caaaaatgccc caaaaaaggg aataaggggg  
5101 acacggaaat gttgaatact catactcttc ctttttcaat attattgaag catttatcag  
5161 ggttattgtc tcatgagcgg atacatattt gaatgtatth agaaaaataa acaaataggg  
5221 gttccgcgca catttccccg aaaagtgcc cctgacgtct aagaaacat tattatcatg  
5281 acattaacct ataaaaatag gcgtatcacg aggccctttc gtctcgcgcg tttcgggtgat  
5341 gacggtgaaa acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg  
5401 gatgccggga gcagacaagc ccgtcagggc gcgtcagcgg gtggttgccg gtgtcggggc  
5461 tggcttaact atgcggcctc agagcagatt gtactgagag tgcaccatat gcggtgtgaa  
5521 ataccgcaca gatgcgtaag gagaaaaata cgcctcaggc gccattcggc attcaggctg  
5581 cgcaactggt ggggaaggcg atcgggtcgg gcctcttcgc tattaogcca gctggcgaaa  
5641 ggggatgtg ctgcaaggcg attaagttgg gtaacgcag ggttttccca gtcacgacgt  
5701 tgtaaaacga cggccagtgc cacgctctcc cttatgcgac tcctgcatta ggaagcagcc  
5761 cagtagtagg ttgaggccgt tgagcaccgc cgcgcgaagg aatgggtgcat gcaaggagat  
5821 ggcgcccac agtccccgg ccacggggcc tgccaccata cccacgccga aacaagcgtc  
5881 catgagcccc aagtggcgag cccgatcttc cccatcgggt atgtcggcga tataggcggc  
5941 agcaaccgca cctgtggcgc cgggtgatgc ggccacgat cgtccggcgt agaggcgatt  
6001 taaagacagg atatcagtg tccaggctct agttttgact caacaatat accagctgaa  
6061 gcctatagag tacgagccat agataaaata aaagatttta tttagtctcc agaaaaaggg  
6121 gggatgaaa gaccccacct gtaggtttgg caagctagct laagtaacgc cattttgcaa  
6181 ggcagtgaaa atacataact gagaatagag aagttcagat caaggttagg aacagagaga  
6241 cagcagataa tgggccaacac aggatatctg tggtaagcag ttctgcccc ggctcagggc  
6301 caagaacaga tggccccag atgcggctcc gccctcagca gtttctagag aacctcaga  
6361 tgtttccagg gtgcccacag gacctgaaaa tgacctgtg ccttatttga actaaccaat  
6421 cagttcgtt ctgcgtctgt ttcgcgcgct tctgctcccc gagctcaata aaagagccca  
6481 caaccctca ctcggcgcgc cagtcctccg atagactcgg tcgcccgggt acccgattc  
6541 ccaataaagc ctcttctgtt ttgatccga atcgtggact cgtgatcct tgggagggc  
6601 tcctcagatt gattgactgc ccacctcggg ggtctttcat ttggagggtc caccgagatt  
6661 tggagacccc tgccatggga ccaccgaccc ccccgcggg aggtaagctg gccagcggtc  
6721 gtttcgtgct tgtctctgtc tttgtgcgtg tttgtgccg catctaattg ttgocctgc  
6781 gtctgtacta gttagctaac tagctctgta tctggcggac ccgtgggtga actgacgagt

**FIG. 13 cont.**

6841 tcggaacacc cggccgcaac cctgggagac gtcccagggg cttcgggggc cgtttttgtg  
6901 gcccgacctg agtccaaaaa tcccgatcgt tttggactct ttggtgcacc ccccttagag  
6961 gagggatatg tggttctggt aggagacgag aacctaaaac agttcccggc tccgtctgaa  
7021 tttttgcttt cggtttgga cgaagccgc gccgcgcgtc ttgtctgctg cagcatcgtt  
7081 ctgtgtgtgc tctgtctgac tgtgtttctg tatttgtctg agaatatggg cccgggctag  
7141 cctgttacca ctcccctaag tttgacctta ggtaactgga aagatgtcga gcggatcgct  
7201 cacaaccagt cggtagatgt caagaagaga cgttgggtta ctttctgctc tgcagaatgg  
7261 ccaaccttta acgtcggatg gccgcgagac ggcaacctta accgagacct catcaccag  
7321 gttaagatca aggtcttttc acctggcccg catggacacc cagaccaggt cccctacatc  
7381 gtgacctggg aagccttggc ttttgacccc cctccctggg tcaagccctt tgtacacccct  
7441 aagcctccgc ctctcttcc tccatccgcc ccgtctctcc cccttgaacc tctctgctcg  
7501 accccgcctc gatcctcctt ttatccagcc ctactcctt ctctaggcgc cnnnncatat  
7561 gagatcttat atggggcacc cccgccctt gtaaacctcc ctgaccctga catgacaaga  
7621 gttactaaca gcccctctct ccaagctcac ttacaggctc totacttagt ccagcacgaa  
7681 gtctggagac ctctggcggc agcctaccaa gaacaactgg accgaccggt ggtacctcac  
7741 ccttacggag tcggcgacac agtgtgggtc cgccgacacc agactaagaa cctagaacct  
7801 cgctggaaag gaccttacac agtctgctg accaccccca ccgccctcaa agtagacggc  
7861 atcgcagctt ggatacacgc cgcccacgtg aaggctgccg accccggggg tggaccatcc  
7921 tctagaccg (SEQ ID NO: 57)

FIG. 14



## GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE

### CROSS-REFERENCE TO RELATED APPLICATIONS

**[0001]** This patent application claims the benefit of U.S. Provisional Patent Application No. 60/884,732, filed Jan. 12, 2007, and U.S. Provisional Patent Application No. 60/885,724, filed Jan. 19, 2007, which are incorporated by reference.

### INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

**[0002]** Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 78,000 Byte ASCII (Text) file named "702330ST25.TXT," created on Jan. 10, 2008.

### BACKGROUND OF THE INVENTION

**[0003]** The gp100 protein has been demonstrated as an antigen in several human cancers, including glioblastoma and melanoma (Saikali et al., *J. Neurooncol.* 81(2): 139-148 (2007); and Cormier et al., *J. Immunother.* 21 (1): 27-31 (1991)). A peptide comprising amino acid residues 154-162 of the gp100 protein (gp100<sub>154-162</sub>) is abundantly presented on the surface of tumors and also binds the MHC molecule HLA-A2 with relative high affinity (Skipper et al., *Int. J. Cancer* 82(5): 669-677 (1999); Parkhurst et al., *J. Immunol.* 157(6):2539-2548. (1996)). Therefore, gp100<sub>154-162</sub> is an ideal tumor target antigen for cancer immunotherapy. T cells with specificity to this epitope, however, are difficult to obtain in HLA-A2-positive patients in amounts useful for therapeutic purposes.

**[0004]** In view of the foregoing, there is a need in the art for gp100-reactive T cells that can be obtained in therapeutic amounts for use in treating cancer patients. The invention provides such T cells and methods of treating cancer, especially melanoma.

### BRIEF SUMMARY OF THE INVENTION

**[0005]** The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigenic specificity for the cancer antigen gp100.

**[0006]** The invention also provides an isolated or purified T cell receptor (TCR) having antigenic specificity for amino acids 154-162 of a gp100 protein (SEQ ID NO: 1). The TCR can comprise any of the specified amino acid sequences as described herein.

**[0007]** The invention also provides related polypeptides and proteins, as well as nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, conjugates, and pharmaceutical compositions relating to the TCRs of the invention.

**[0008]** Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention. The inventive method of detecting the presence of cancer in a host comprises (i) contacting a sample comprising cells of the cancer with any of the inventive human cells, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, or antibodies, or antigen binding portions thereof,

described herein, thereby forming a complex, and (ii) detecting the complex, wherein detection of the complex is indicative of the presence of cancer in the host.

**[0009]** The inventive method of treating or preventing cancer in a host comprises administering to the host any of the inventive pharmaceutical compositions described herein in an amount effective to treat or prevent cancer in the host.

### BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

**[0010]** FIG. 1 is a graph of the amount of IFN- $\gamma$  (pg/ml) secreted by T cells from bulk cultures of HLA-A2 transgenic mice immunized with gp100<sub>154-162</sub> peptide upon stimulation with (1) T2 cells pulsed with 0.001 (bar with diagonal lines), 0.01 (bar with vertical lines), 0.1 (criss-crossed bar), or 1  $\mu$ M (checkered bar) gp100<sub>154-162</sub> peptide or 1  $\mu$ M  $\beta$ -galactosidase (dotted bar), or (2) melanoma cells: Mel A375 cells (HLA-A2<sup>+</sup>/gp100<sup>-</sup>; white bar) or Mel 526 (HLA-A2<sup>+</sup>/human gp100<sup>+</sup> black bar).

**[0011]** FIG. 2 is a set of flow cytometry graphs of T cells from bulk cultures of HLA-A2 transgenic mice immunized with gp100<sub>154-162</sub> peptide stained with (1) PE-linked gp100<sub>154-162</sub> tetramer and FITC-labeled anti-mouse CD8 antibodies (left box) or (2) PE-linked gp100<sub>209-217</sub> tetramer and FITC-labeled anti-mouse CD8 antibodies (middle box). gp100<sub>209-217</sub>-specific human T cell clone were stained with PE-linked gp100<sub>209-217</sub> tetramer and FITC-labeled anti-human CD8 antibodies as a control (right box).

**[0012]** FIG. 3 is a graph of amount of IFN- $\gamma$  (pg/ml) secreted by clone Sp(0.01)A upon stimulation with (1) T2 cells pulsed with a negative control peptide (T2+gp100(209-2M); white bar) or gp100<sub>154-162</sub> peptide (black bar) or (2) melanoma cells: HLA-A2<sup>+</sup>/gp100<sup>+</sup>Mel 526 cells (criss-crossed bar) and with gp100<sup>-</sup> Mel A375 cells (MelA375).

**[0013]** FIG. 4 is a set of flow cytometry graphs of clone Sp(0.01)A upon staining with (1) PE-labeled gp100<sub>154-162</sub> tetramer at a 1:100 dilution and FITC-labeled anti-mouse CD8 antibodies (left box), (2) PE-labeled gp100<sub>154-162</sub> tetramer at a 1:1000 dilution and FITC-labeled anti-mouse CD8 antibodies (middle box), and (3) PE-labeled gp100<sub>209-217</sub> tetramer and FITC-labeled anti-mouse CD8 antibodies (right box).

**[0014]** FIG. 5A is the nucleotide and amino acid sequences of the alpha chain of the TCR of clone Sp(0.01)A.

**[0015]** FIG. 5B is the nucleotide and amino acid sequences of the beta chain of the TCR of clone Sp(0.01)A.

**[0016]** FIG. 6 are flow cytometry graphs of PBLs mock electroporated (top row) or electroporated with RNA encoding Sp(0.01)A TCR chains (bottom row) stained with (1) PE-labeled gp100<sub>154-162</sub> tetramer and APC-labeled anti-human CD8 antibodies (left boxes), (2) FITC-labeled mouse TCR beta chain antibodies and APC-labeled anti-human CD8 antibodies (middle boxes), and (3) PE-labeled gp100<sub>154-162</sub> tetramer at a 1:50 dilution or 1:100 dilution (right boxes).

**[0017]** FIG. 7A is graph of the amount of IFN- $\gamma$  produced by human PBLs electroporated with (1) Sp(0.01)A TCR RNA (closed squares), (2) human gp100<sub>209-217</sub> TCR RNA (closed circles), (3) human MART-1 TCR RNA (open circles), (4) human/mouse hybrid MART-1 TCR RNA (open triangles), and p53 TCR RNA (open diamonds), upon stimulation with T2 cells pulsed with 10<sup>-6</sup>, 10<sup>-7</sup>, 10<sup>-8</sup>, 10<sup>-9</sup>, 10<sup>-10</sup>, or 10<sup>-11</sup> M gp100<sub>154-162</sub> peptide or 10<sup>-6</sup> M negative control peptide.

**[0018]** FIG. 7B is a graph of the amount of IFN- $\gamma$  produced by human PBLs electroporated with (1) Sp(0.01)A TCR RNA (black bars), (2) human gp100<sub>209-217</sub> TCR RNA (white bars), (3) human MART-1 TCR RNA (dotted bars), (4) human/mouse hybrid MART-1 TCR RNA (criss-crossed bars), and p53 TCR RNA (bars with diagonal lines), upon stimulation with melanoma cells (Mel 938 (HLA-A2<sup>-</sup>/gp100<sup>+</sup>/p53<sup>-</sup>, MART-1<sup>+</sup>), Mel 888 (HLA-A2<sup>-</sup>/gp100<sup>+</sup>/p53<sup>-</sup>/MART-1<sup>+</sup>), Mel A375 (HLA-A2<sup>+</sup>/gp100<sup>-</sup>/p53<sup>-</sup>/gp100<sup>-</sup>), Mel 526 (HLA-A2<sup>+</sup>/gp100<sup>+</sup>/p53<sup>+</sup>/MART-1<sup>+</sup>), Mel Sk 23 (HLA-A2<sup>+</sup>/gp100<sup>-</sup>/p53<sup>-</sup>/MART-1<sup>+</sup>), and Mel 624 (HLA-A2<sup>+</sup>/gp100<sup>+</sup>/p53<sup>+</sup>/MART-1<sup>+</sup>)) and breast carcinoma line MDA-231 (HLA-A2<sup>+</sup>/gp100<sup>-</sup>/p53<sup>+</sup>/MART-1<sup>-</sup>).

**[0019]** FIG. 8A are flow cytometry graphs of human CD4<sup>+</sup> T cells (top row) or human CD8<sup>+</sup> T cells (bottom row) mock electroporated (left column) or electroporated with Sp(0.01)A TCR RNA (right column) stained with PE-labeled gp100<sub>154-162</sub> tetramer and FITC-labeled anti-human CD8 antibodies.

**[0020]** FIG. 8B is a graph of the IFN- $\gamma$  produced by CD4<sup>+</sup> T cells (closed squares) or CD8<sup>+</sup> T cells (open circles) electroporated with Sp(0.01)A TCR RNA upon stimulation with T2 cells pulsed with 10<sup>-6</sup>, 10<sup>-7</sup>, 10<sup>-8</sup>, 10<sup>-9</sup>, 10<sup>-10</sup>, or 10<sup>-11</sup> M gp100<sub>154-162</sub> peptide or 10<sup>-6</sup> M negative control peptide.

**[0021]** FIG. 8C is a graph of the IFN- $\gamma$  produced by CD4<sup>+</sup> T cells (black bars) or CD8<sup>+</sup> T cells (white bars) electroporated with Sp(0.01)A TCR RNA upon stimulation with melanoma cells: Mel 938, Mel 888, Mel A375, Mel 526, Mel Sk 23, and Mel 624.

**[0022]** FIG. 9A are flow cytometry graphs of human PBLs mock electroporated (left column), electroporated with RNA encoding human gp100<sub>154-162</sub> TCR from clone 1 (upper middle box) or from clone 2 (lower middle box) or electroporated with RNA encoding Sp(0.01)A mouse TCR (right column) and stained with PE-labeled gp100<sub>154-162</sub> tetramer and APC-labeled anti-human CD8 antibodies.

**[0023]** FIG. 9B is a graph of the IFN- $\gamma$  produced by human PBLs electroporated with RNA encoding a human gp100-specific TCR (from clone 1; closed squares in top graph and black bars in bottom graph) or encoding the mouse gp100-specific TCR (from clone Sp(0.01)A; closed circles in top graph and white bars in bottom graph) upon stimulation with T2 cells pulsed with 10<sup>-6</sup>, 10<sup>-7</sup>, 10<sup>-8</sup>, 10<sup>-9</sup>, 10<sup>-10</sup>, or 10<sup>-11</sup> M gp100<sub>154-162</sub> peptide or negative control peptide (top graph) or with melanoma cells: Mel 938, Mel 888, Mel A375, Mel 526, Mel Sk 23, and Mel 624 (bottom graph).

**[0024]** FIG. 9C is a graph of the IFN- $\gamma$  produced by human PBLs electroporated with RNA encoding a human gp100-specific TCR (from clone 2; closed squares in top graph and black bars in bottom graph) or encoding the mouse gp100-specific TCR (from clone Sp(0.01)A; closed circles in top graph and white bars in bottom graph) upon stimulation with T2 cells pulsed with 10<sup>-6</sup>, 10<sup>-7</sup>, 10<sup>-8</sup>, 10<sup>-9</sup>, 10<sup>-10</sup>, 10<sup>-11</sup>, or 10<sup>-12</sup> M gp100<sub>154-162</sub> peptide or negative control peptide (top graph) or with melanoma cells: Mel 938, Mel 888, Mel A375, Mel 526 (HLA-A2<sup>+</sup>/gp100<sup>+</sup>, Mel Sk 23, and Mel 624 (bottom graph).

**[0025]** FIG. 10A depicts the nucleotide sequences encoding the gp100-specific TCR alpha and beta chains from clone T2(1)B.

**[0026]** FIG. 10B depicts the nucleotide sequences encoding the gp100-specific TCR alpha and beta chains from clone Sp(0.1)A10.

**[0027]** FIG. 10C depicts the nucleotide sequences encoding the gp100-specific TCR alpha and beta chains from clone T2(1)C.

**[0028]** FIG. 11A and FIG. 11B depict the relative activities of a mouse gp100:154-162 specific TCR and a human MART-1 specific (F4) TCR. FIG. 11A depicts the IFN- $\gamma$  (pg/ml) released by cells expressing the mouse gp100:154-162 specific TCR (black squares) or the human MART-1 specific (F4) TCR (white circles) in response to relevant peptide pulsed cells (gp100:154-162 peptide or MART-1 peptide). FIG. 11B depicts the IFN- $\gamma$  (pg/ml) released by cells expressing the mouse gp100:154-162 specific TCR (black bars) or the human MART-1 specific (F4) TCR (white bars) in response to HLA-A2+ tumor cells (Mel 526, Mel SK23, Mel 624) or HLA-A2- tumor cells (Mel 938).

**[0029]** FIG. 12 depicts the percent lysis of target tumor cells by CD4+ PBL (left panels) or CD8+ PBL (right panels) retrovirally transduced with gp100:154-162 TCR (diamonds), DMF4 TCR (circles), DMF5 (squares), mDMF5 (triangles), or with control (GFP designated by "X"). The target tumor cells were 526 mel (top panels) or 624 mel (bottom panels).

**[0030]** FIG. 13 depicts the nucleotide sequence of anti-gp100 TCR vector MSGV1-154-AIB.

**[0031]** FIG. 14 depicts the map of plasmid DNA for vector MSGV1-154-AIB.

#### DETAILED DESCRIPTION OF THE INVENTION

**[0032]** The invention provides a human cell comprising a murine TCR having antigenic specificity for gp100. The human cell can be any cell originating from a human. For instance, the human cell of the invention can be a primary cell directly obtained from a human. Alternatively, the human cell can be a cell of a cultured human cell line. Also, the inventive human cell can be a cell originating from any human tissue. For instance, the human cell can be a blood cell (e.g., red blood cell, white blood cell, lymphocyte, etc.), an epithelial cell, an endothelial cell, muscle cell, hepatocyte, brain cells, renal cell, and the like. Preferably, the human cell is a blood cell. More preferably, the human cell is a lymphocyte. Most preferably, the lymphocyte is a T lymphocyte (i.e., T cell).

**[0033]** For purposes herein, the T cell can be any T cell, such as a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupT1, etc., or a T cell obtained from a human. If obtained from a human, the T cell can be obtained from numerous sources, including but not limited to blood, bone marrow, lymph node, the thymus, or other tissues or fluids. T cells can also be enriched for or purified. The T cell can be any type of T cell and can be of any developmental stage, including but not limited to, CD4<sup>+</sup>/CD8<sup>+</sup> double positive T cells, CD4<sup>+</sup> helper T cells, e.g., Th<sub>1</sub> and Th<sub>2</sub> cells, CD8<sup>+</sup> T cells (e.g., cytotoxic T cells), peripheral blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor infiltrating cells (TILs), memory T cells, naïve T cells, and the like. Preferably, the T cell is a CD8<sup>+</sup> T cell or a CD4<sup>+</sup> T cell.

**[0034]** The human cell of the invention comprises a murine TCR through means of, e.g., recombinant technology. As used herein, the term "murine TCR" means a TCR that is derived from a mouse, i.e., a TCR that originated from or was, at one time, expressed by a mouse T cell. Desirably, the murine TCR is expressed on the surface of the human cell.

**[0035]** The murine TCR of the invention has antigenic specificity for the gp100 protein, e.g., human gp100. gp100, also known in the art as SILV, SI, SIL, ME20, PMEL17, or D12S53E, is a protein known to play an important role in regulating mammalian pigmentation (Hoashi et al., *J. Biol. Chem.* 280: 14006-14016 (e-publication on Jan. 28, 2005)) and is known as a cancer antigen expressed by human tumors, including melanoma and colorectal tumors (Tartaglia et al. (2001), supra). The amino acid and nucleotide sequences of human gp100 are published in the GenBank database of the National Center for Biotechnology Information (NCBI) as GenBank Accession No. NP\_008859 (amino acid sequence) and GenBank Accession No. NM\_006928.3 (nucleotide sequence). The amino acid sequence of a human gp100 is set forth herein as SEQ ID NO: 1.

**[0036]** As used herein, the phrase “having antigenic specificity,” or like phrase, means that the TCR can specifically bind to and immunologically recognize gp100, or an epitope thereof, such that binding of the TCR to gp100, or the epitope thereof, elicits an immune response.

**[0037]** In a preferred embodiment of the invention, the murine TCR has antigenic specificity for amino acids 154-162 of a human gp100 of SEQ ID NO: 1, namely KTWGQY-WQV (SEQ ID NO: 34). In this regard, the invention also provides an isolated or purified TCR having antigenic specificity for amino acids 154-162 of a gp100 protein (SEQ ID NO: 1).

**[0038]** The TCR of the invention (including the murine TCR of the inventive human cells) generally comprises two polypeptides (i.e., polypeptide chains), such as an  $\alpha$  chain of a TCR, a  $\beta$  chain of a TCR, a  $\gamma$  chain of a TCR, a  $\delta$  chain of a TCR, or a combination thereof. Such polypeptide chains of TCRs are known in the art. The polypeptides of the inventive TCR can comprise any amino acid sequence, provided that the TCR has antigenic specificity for gp100, e.g., amino acids 154-162 of a human gp100 of SEQ ID NO: 1.

**[0039]** In a preferred embodiment of the invention, the TCR comprises two polypeptide chains, each of which comprises a variable region, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 9. In a more preferred embodiment, the TCR comprises (i) a first polypeptide chain comprising SEQ ID NO: 2 and a second polypeptide chain comprising SEQ ID NO: 3, (ii) a first polypeptide chain comprising SEQ ID NO: 4 and a second polypeptide chain comprising SEQ ID NO: 5, (iii) a first polypeptide chain comprising SEQ ID NO: 6 and a second polypeptide chain comprising SEQ ID NO: 7, or (iv) a first polypeptide chain comprising SEQ ID NO: 8 and a second polypeptide chain comprising SEQ ID NO: 9.

**[0040]** In a most preferred embodiment of the invention, the TCR comprises a first polypeptide chain comprising SEQ ID NO: 2 and a second polypeptide chain comprising SEQ ID NO: 3.

**[0041]** Alternatively or additionally, the TCR can comprise an  $\alpha$  chain of a TCR and a  $\beta$  chain of a TCR. Each of the  $\alpha$  chain and  $\beta$  chain of the inventive TCR can independently comprise any amino acid sequence. Preferably, the  $\alpha$  chain comprises the variable region of any of SEQ ID NOs: 2, 4, 6, and 8. In this regard, the inventive TCR can comprise the amino acid sequence of any of SEQ ID NOs: 10, 12, 14, and 16. An inventive TCR of this type can be paired with any  $\beta$  chain of a TCR. Preferably, the  $\beta$  chain of the inventive TCR comprises the variable region of any of SEQ ID NOs: 3, 5, 7,

and 9. In this regard, the inventive TCR can comprise the amino acid sequence of any of SEQ ID NOs: 11, 13, 15, and 17.

**[0042]** In a preferred embodiment, the TCR comprises an  $\alpha$  chain comprising SEQ ID NO: 10 and a  $\beta$  chain comprising SEQ ID NO: 11, an  $\alpha$  chain comprising SEQ ID NO: 12 and a  $\beta$  chain comprising SEQ ID NO: 13, an  $\alpha$  chain comprising SEQ ID NO: 14 and a  $\beta$  chain comprising SEQ ID NO: 15, or an  $\alpha$  chain comprising SEQ ID NO: 16 and a  $\beta$  chain comprising SEQ ID NO: 17.

**[0043]** In a more preferred embodiment, the TCR comprises an  $\alpha$  chain comprising SEQ ID NO: 10 and a  $\beta$  chain comprising SEQ ID NO: 11, which is the full length  $\alpha$  and  $\beta$  chains of the T cell clone termed Sp(0.01)A.

**[0044]** The TCRs of the invention can comprise one or more portions of a human TCR, such that the TCR, when administered to a human, is not rejected by the immune system of the human (as in e.g., graft vs. host disease). The portion can be, for example, a variable region of a human TCR or a constant region of a human TCR. Desirably, the portion is a constant region of a human TCR. The constant region of a human can, for example, comprise the amino acid sequence set forth in SEQ ID NOs: 55 and 56 (constant regions of alpha and beta chains, respectively). In this regard, the invention provides a hybrid TCR comprising a human constant region and a murine variable region, wherein the TCR is specific for gp100<sub>154-162</sub>. Alternatively, the portion can be a few amino acids of a human TCR, such that the TCR, which is mostly murine, is “humanized.” Methods of making such hybrid TCRs are known in the art. See, for example, Cohen et al., *Cancer Res.* 66: 8878-8886 (2006).

**[0045]** The invention also provides an isolated or purified polypeptide comprising a functional portion of any of the TCRs described herein. The term “polypeptide” as used herein includes oligopeptides and refers to a single chain of amino acids connected by one or more peptide bonds.

**[0046]** With respect to the inventive polypeptides, the functional portion can be any portion comprising contiguous amino acids of the TCR of which it is a part, provided that the functional portion specifically binds to amino acids 154-162 of gp100 (SEQ ID NO: 1). The term “functional portion” when used in reference to a TCR refers to any part or fragment of the TCR of the invention, which part or fragment retains the biological activity of the TCR of which it is a part (the parent TCR). Functional portions encompass, for example, those parts of a TCR that retain the ability to specifically bind to gp100, or detect, treat, or prevent cancer, to a similar extent, the same extent, or to a higher extent, as the parent TCR. In reference to the parent TCR, the functional portion can comprise, for instance, about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95%, or more, of the parent TCR.

**[0047]** The functional portion can comprise additional amino acids at the amino or carboxy terminus of the portion, or at both termini, which additional amino acids are not found in the amino acid sequence of the parent TCR. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, e.g., specifically binding to gp100, having the ability to detect cancer, treat or prevent cancer. More desirably, the additional amino acids enhance the biological activity, as compared to the biological activity of the parent TCR.

**[0048]** The polypeptide can comprise, for instance, a functional portion of the TCR, wherein the functional portion is the variable region of the inventive TCR. In this regard, the

polypeptide can comprise the amino acid sequence of any of SEQ ID NOs: 2 to 9, or a combination thereof. For instance, the polypeptide can comprise the amino acid sequence of SEQ ID NO: 2 and SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, or SEQ ID NO: 8 and SEQ ID NO: 9. Preferably, the inventive polypeptide comprises SEQ ID NO: 2 (the variable region of an  $\alpha$  chain) or 3 (the variable region of a  $\beta$  chain), or both SEQ ID NOs: 2 and 3.

**[0049]** Alternatively or additionally, the inventive polypeptide can comprise the entire length of an  $\alpha$  or  $\beta$  chain of one of the TCRs described herein. In this regard, the inventive polypeptide can comprise an amino acid sequence of any of SEQ ID NOs: 10 to 17. Alternatively, the polypeptide of the invention can comprise both chains of the TCRs described herein. For example, the inventive polypeptide can comprise both amino acid sequences of SEQ ID NOs: 10 and 11, SEQ ID NOs: 12 and 13, SEQ ID NOs: 14 and 15, or SEQ ID NOs: 16 and 17.

**[0050]** The invention further provides an isolated or purified protein comprising at least one of the polypeptides described herein. By "protein" is meant a molecule comprising one or more polypeptide chains.

**[0051]** The protein of the invention can comprise, for example, a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 10 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 11. In this instance, the protein of the invention can be a TCR. Alternatively, if, for example, the protein comprises a single polypeptide chain comprising SEQ ID NO: 2 and SEQ ID NO: 3, or SEQ ID NO: 10 and SEQ ID NO: 11, or if the first and/or second polypeptide chain(s) of the protein further comprise(s) other amino acid sequences, e.g., an amino acid sequence encoding an immunoglobulin or a portion thereof, then the inventive protein can be a fusion protein. In this regard, the invention also provides a fusion protein comprising at least one of the inventive polypeptides described herein along with at least one other polypeptide. The other polypeptide can exist as a separate polypeptide of the fusion protein, or can exist as a polypeptide, which is expressed in frame (in tandem) with one of the inventive polypeptides described herein. The other polypeptide can encode any peptidic or proteinaceous molecule, or a portion thereof, including, but not limited to an immunoglobulin, a TCR co-receptor (e.g., CD3, CD4, CD8), an MHC molecule (e.g., HLA-A2), or a portion thereof, etc.

**[0052]** The fusion protein can comprise one or more copies of the inventive polypeptide and/or one or more copies of the other polypeptide. For instance, the fusion protein can comprise 1, 2, 3, 4, 5, or more, copies of the inventive polypeptide and/or of the other polypeptide. Suitable methods of making fusion proteins are known in the art, and include, for example, recombinant methods. See, for instance, Choi et al., *Mol. Biotechnol.* 31: 193-202 (2005).

**[0053]** In a preferred embodiment of the invention, the protein is a soluble protein, e.g., a soluble TCR. Soluble TCRs, as well as methods of making the same, are known in the art. See, for example, Jesson et al., *Internatl. Immunol.* 10: 27-35 (1998); Boulter et al., *Protein Engineering Design & Selection* 16: 707-711 (2003); Weber et al., *Nature* 356: 793-796 (1992); International Patent Application Publication No. WO 96/13593; and U.S. Pat. No. 6,080,840.

**[0054]** The protein of the invention can be a recombinant antibody comprising at least one of the inventive polypeptides described herein. As used herein, "recombinant antibody" refers to a recombinant (e.g., genetically engineered) protein comprising at least one of the polypeptides of the invention and a polypeptide chain of an antibody, or a portion thereof. The polypeptide of an antibody, or portion thereof, can be a heavy chain, a light chain, a variable or constant region of a heavy or light chain, a single chain variable fragment (scFv), or an Fc, Fab, or F(ab)<sub>2</sub>' fragment of an antibody, etc. The polypeptide chain of an antibody, or portion thereof, can exist as a separate polypeptide of the recombinant antibody. Alternatively, the polypeptide chain of an antibody, or portion thereof, can exist as a polypeptide, which is expressed in frame (in tandem) with the polypeptide of the invention. The polypeptide of an antibody, or portion thereof, can be a polypeptide of any antibody or any antibody fragment, including any of the antibodies and antibody fragments described herein.

**[0055]** Included in the scope of the invention are functional variants of the inventive TCRs, polypeptides, and proteins described herein. The term "functional variant" as used herein refers to a TCR, polypeptide, or protein having substantial or significant sequence identity or similarity to a parent TCR, polypeptide, or protein, which functional variant retains the biological activity of the TCR, polypeptide, or protein of which it is a variant. Functional variants encompass, for example, those variants of the TCR, polypeptide, or protein described herein (the parent TCR, polypeptide, or protein) that retain the ability to specifically bind to gp100 (e.g., gp100<sub>154-162</sub>), to a similar extent, the same extent, or to a higher extent, as the parent TCR, polypeptide, or protein. In reference to the parent TCR, polypeptide, or protein, the functional variant can, for instance, be at least about 30%, 50%, 75%, 80%, 90%, 98% or more identical in amino acid sequence to the parent TCR, polypeptide, or protein.

**[0056]** The functional variant can, for example, comprise the amino acid sequence of the parent TCR, polypeptide, or protein with at least one conservative amino acid substitution. Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and/or chemical properties is exchanged for another amino acid that has the same chemical or physical properties. For instance, the conservative amino acid substitution can be an acidic amino acid substituted for another acidic amino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.

**[0057]** Alternatively or additionally, the functional variants can comprise the amino acid sequence of the parent TCR, polypeptide, or protein with at least one non-conservative amino acid substitution. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with or inhibit the biological activity of the functional variant. Preferably, the non-conservative amino acid substitution enhances the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the parent TCR, polypeptide, or protein.

**[0058]** For instance, the invention provides a functional variant of the TCR, polypeptide, and protein comprising the amino acid sequence of SEQ ID NO: 5, 9, 13 or 17, wherein the functional variant comprises one, two, three, or four amino acid substitutions in SEQ ID NO: 5, 9, 13, or 17. Desirably, the functional variant comprises the amino acid sequence of SEQ ID NO: 52 or 53, wherein X is any amino acid. More desirably, the X at position 17 of SEQ ID NO: 52 or the X at position 46 of SEQ ID NO: 53 is a negatively charged amino acid.

**[0059]** Additionally, the invention provides a functional variant of the TCR, polypeptide, and protein comprising the amino acid sequence of SEQ ID NO: 11, wherein the functional variant comprises one or two amino acid substitutions in SEQ ID NO: 11. Desirably, the functional variant comprises the amino acid sequence of SEQ ID NO: 54, wherein X is any amino acid.

**[0060]** The TCR, polypeptide, or protein can consist essentially of the specified amino acid sequence or sequences described herein, such that other components of the functional variant, e.g., other amino acids, do not materially change the biological activity of the functional variant. In this regard, the inventive TCR, polypeptide, or protein can, for example, consist essentially of the amino acid sequence of any of SEQ ID NOs: 2 to 9, or a combination thereof. Also, for instance, the inventive TCRs, polypeptides, or proteins can consist essentially of the amino acid sequence(s) of any of SEQ ID NOs: 10 to 17, or a combination thereof.

**[0061]** The TCRs, polypeptides, and proteins of the invention (including functional portions and functional variants) can be of any length, i.e., can comprise any number of amino acids, provided that the TCRs, polypeptides, or proteins (or functional portions or functional variants thereof) retain their biological activity, e.g., the ability to specifically bind to gp100, detect cancer in a host, or treat or prevent cancer in a host, etc. For example, the polypeptide can be 50 to 5000 amino acids long, such as 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids in length. In this regard, the polypeptides of the invention also include oligopeptides.

**[0062]** The TCRs, polypeptides, and proteins of the invention (including functional portions and functional variants) of the invention can comprise synthetic amino acids in place of one or more naturally-occurring amino acids. Such synthetic amino acids are known in the art, and include, for example, aminocyclohexane carboxylic acid, norleucine,  $\alpha$ -amino n-decanoic acid, homoserine, S-acetylaminoethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine,  $\beta$ -phenylserine,  $\beta$ -hydroxyphenylalanine, phenylglycine,  $\alpha$ -naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine,  $\alpha$ -aminocyclopentane carboxylic acid,  $\alpha$ -aminocyclohexane carboxylic acid,  $\alpha$ -aminocycloheptane carboxylic acid,  $\alpha$ -(2-amino-2-norbornane)-carboxylic acid,  $\alpha,\gamma$ -diaminobutyric acid,  $\alpha,\beta$ -diaminopropionic acid, homophenylalanine, and  $\alpha$ -tert-butylglycine.

**[0063]** The TCRs, polypeptides, and proteins of the invention (including functional portions and functional variants) can be glycosylated, amidated, carboxylated, lipidated, phosphorylated, esterified, N-acylated, cyclized via, e.g., a disulfide bridge, or converted into an acid addition salt and/or optionally dimerized or polymerized, or conjugated.

**[0064]** When the TCRs, polypeptides, and proteins of the invention (including functional portions and functional variants) are in the form of a salt, preferably, the polypeptides are in the form of a pharmaceutically acceptable salt. Suitable pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, and sulphuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulphonic acids, for example, p-toluenesulphonic acid.

**[0065]** The TCR, polypeptide, and/or protein of the invention (including functional portions and functional variants thereof) can be obtained by methods known in the art. Suitable methods of de novo synthesizing polypeptides and proteins are described in references, such as Chan et al., *Fmoc Solid Phase Peptide Synthesis*, Oxford University Press, Oxford, United Kingdom, 2005; *Peptide and Protein Drug Analysis*, ed. Reid, R., Marcel Dekker, Inc., 2000; *Epitope Mapping*, ed. Westwood et al., Oxford University Press, Oxford, United Kingdom, 2000; and U.S. Pat. No. 5,449,752. Also, polypeptides and proteins can be recombinantly produced using the nucleic acids described herein using standard recombinant methods. See, for instance, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3<sup>rd</sup> ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 2001; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, NY, 1994. Further, some of the TCRs, polypeptides, and proteins of the invention (including functional portions and functional variants thereof) can be isolated and/or purified from a source, such as a plant, a bacterium, an insect, a mammal, e.g., a rat, a human, etc. Methods of isolation and purification are well-known in the art. Alternatively, the TCRs, polypeptides, and/or proteins described herein (including functional portions and functional variants thereof) can be commercially synthesized by companies, such as Synpep (Dublin, Calif.), Peptide Technologies Corp. (Gaithersburg, Md.), Altor Bioscience (Miramar, Fla.), and Multiple Peptide Systems (San Diego, Calif.). In this respect, the inventive TCRs, polypeptides, and proteins can be synthetic, recombinant, isolated, and/or purified.

**[0066]** Further provided by the invention is a nucleic acid comprising a nucleotide sequence encoding any of the TCRs, polypeptides, or proteins described herein (including functional portions and functional variants thereof).

**[0067]** By "nucleic acid" as used herein includes "polynucleotide," "oligonucleotide," and "nucleic acid molecule," and generally means a polymer of DNA or RNA, which can be single-stranded or double-stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered internucleotide linkage, such as a phosphoramidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. It is generally preferred that the nucleic acid does not comprise any insertions, deletions, inversions, and/or substitutions. However, it may be suitable in some instances, as discussed herein, for the nucleic acid to comprise one or more insertions, deletions, inversions, and/or substitutions.

**[0068]** Preferably, the nucleic acids of the invention are recombinant. As used herein, the term "recombinant" refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic

acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above. For purposes herein, the replication can be in vitro replication or in vivo replication.

**[0069]** The nucleic acids can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. See, for example, Sambrook et al., supra, and Ausubel et al., supra. For example, a nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides). Examples of modified nucleotides that can be used to generate the nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N<sup>6</sup>-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N<sup>6</sup>-substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N<sup>6</sup>-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the invention can be purchased from companies, such as Macromolecular Resources (Fort Collins, Colo.) and Synthegen (Houston, Tex.).

**[0070]** The nucleic acid can comprise any nucleotide sequence which encodes any of the TCRs, polypeptides, or proteins, or functional portions or functional variants thereof. For example, the nucleic acid can comprise a nucleotide sequence comprising any of SEQ ID NOs: 18 to 25 (which encode variable regions), SEQ ID NOs: 26 to 33 (which encode full length chains), or any combination thereof. The nucleotide sequence alternatively can comprise a nucleotide sequence which is degenerate to any of the aforementioned nucleotide sequences.

**[0071]** The nucleic acid of the invention can comprise a coding sequence that has undergone codon optimization, i.e., the non-native coding sequence is a product of codon optimization. Codon optimization is a strategy in which codons within a cloned gene, which codons are not generally used by the host cell translation system, termed "rare codons," are changed by in vitro mutagenesis to preferred codons without changing the amino acids of the synthesized protein (Bradell-Tretheway et al., *J Virol Meth* 111: 145-156 (2003); Ramakrishna et al., *J Virol* 78: 9174-9189 (2004)). In addition, the inventive nucleic acid can be further modified, e.g., codon optimized, to improve the folding of the RNA, such that the folding of the RNA transcript encoded by the nucleic acid is minimized. Without being bound to any particular theory, it is currently believed that the predicted minimized free energy, as determined by, for example, molecular modeling computer programs, correlates with minimized folding of the RNA, which, in turn, facilitates ribosome binding to the RNA and allows efficient expression of the RNA.

**[0072]** A given nucleotide sequence can be codon-optimized through the use of publicly-available computer programs, such as "Ugene: A Web-based DNA codon optimization algorithm," available on the internet at the website for the Recombinant Vaccine Center at the University of Pittsburgh Molecular Medicine Institute, and the "Codon Optimizer Tool," which is freeware available on the internet. Alternatively, a nucleotide sequence can be optimized through the services of companies, such as Blue Heron Bio, Inc. (Bothell, Wash.) and GenScript Corp. (Piscataway, N.J.).

**[0073]** The invention also provides an isolated or purified nucleic acid comprising a nucleotide sequence which is complementary to the nucleotide sequence of any of the nucleic acids described herein or a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of any of the nucleic acids described herein.

**[0074]** The nucleotide sequence which hybridizes under stringent conditions preferably hybridizes under high stringency conditions. By "high stringency conditions" is meant that the nucleotide sequence specifically hybridizes to a target sequence (the nucleotide sequence of any of the nucleic acids described herein) in an amount that is detectably stronger than non-specific hybridization. High stringency conditions include conditions which would distinguish a polynucleotide with an exact complementary sequence, or one containing only a few scattered mismatches from a random sequence that happened to have a few small regions (e.g., 3-10 bases) that matched the nucleotide sequence. Such small regions of complementarity are more easily melted than a full-length complement of 14-17 or more bases, and high stringency hybridization makes them easily distinguishable. Relatively high stringency conditions would include, for example, low salt and/or high temperature conditions, such as provided by about 0.02-0.1 M NaCl or the equivalent, at temperatures of about 50-70° C. Such high stringency conditions tolerate little, if any, mismatch between the nucleotide sequence and the template or target strand, and are particularly suitable for detecting expression of any of the inventive TCRs. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide.

**[0075]** The nucleic acids of the invention can be incorporated into a recombinant expression vector. In this regard, the invention provides recombinant expression vectors comprising any of the nucleic acids of the invention. For purposes herein, the term "recombinant expression vector" means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors of the invention are not naturally-occurring as a whole. However, parts of the vectors can be naturally-occurring. The inventive recombinant expression vectors can comprise any type of nucleotides, including, but not limited to DNA and RNA, which can be single-stranded or double-stranded, synthesized or obtained in part from natural sources, and which can contain natural, non-natural or altered nucleotides. The recombinant expression vectors can comprise naturally-occurring, non-naturally-occurring internucleotide linkages, or both types of linkages. Preferably, the

non-naturally occurring or altered nucleotides or internucleotide linkages does not hinder the transcription or replication of the vector.

**[0076]** The recombinant expression vector of the invention can be any suitable recombinant expression vector, and can be used to transform or transfect any suitable host. Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses. The vector can be selected from the group consisting of the pUC series (Fermentas Life Sciences), the pBluescript series (Stratagene, LaJolla, Calif.), the pET series (Novagen, Madison, Wis.), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, Calif.). Bacteriophage vectors, such as  $\lambda$ GT10,  $\lambda$ GT11,  $\lambda$ ZapII (Stratagene),  $\lambda$ EMBL4, and  $\lambda$ NM1149, also can be used. Examples of plant expression vectors include pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech).

**[0077]** Preferably, the recombinant expression vector is a viral vector. Viral vectors are known in the art and include, for instance, retroviral vectors, adenoviral vectors, aden-associated viral vectors, pox viral vectors, vaccinia viral vectors, modified vaccinia viral vectors, and herpes simplex viral vectors. More preferably, the viral vector is a retroviral vector or a lentiviral vector.

**[0078]** The recombinant expression vector can be a yeast expression vector, such as, for example, pYES-DEST52, pAO815, pGAPZ, pPIC3.5 k, pYC2/CT, pYD1, pESC-LEU, and the like. The yeast in which the nucleic acid is to be expressed can be any yeast, such as, for instance, *S. pombe*, *S. cerevisiae*, *Pichia pastoris*, etc. The yeast expression vector can be an inducible expression vector, e.g., a heat-inducible expression vector, or can be an expression vector which mediates constitutive expression. Such yeast expression vectors are known in the art.

**[0079]** The recombinant expression vectors of the invention can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., supra, and Ausubel et al., supra. Constructs of expression vectors, which are circular or linear, can be prepared to contain a replication system functional in a prokaryotic or eukaryotic host cell. Replication systems can be derived, e.g., from ColE1, 2 $\mu$  plasmid,  $\lambda$ , SV40, bovine papilloma virus, and the like.

**[0080]** Desirably, the recombinant expression vector comprises regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host (e.g., bacterium, fungus, plant, or animal) into which the vector is to be introduced, as appropriate and taking into consideration whether the vector is DNA- or RNA-based.

**[0081]** The recombinant expression vector can include one or more marker genes, which allow for selection of transformed or transfected hosts. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like. Suitable marker genes for the inventive expression vectors include, for instance, neomycin/G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance genes.

**[0082]** The recombinant expression vector can comprise a native or normative promoter operably linked to the nucleotide sequence encoding the TCR, polypeptide, or protein (including functional portions and functional variants

thereof), or to the nucleotide sequence which is complementary to or which hybridizes to the nucleotide sequence encoding the TCR, polypeptide, or protein. The selection of promoters, e.g., strong, weak, inducible, tissue-specific and developmental-specific, is within the ordinary skill of the artisan. Similarly, the combining of a nucleotide sequence with a promoter is also within the skill of the artisan. The promoter can be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, and a promoter found in the long-terminal repeat of the murine stem cell virus.

**[0083]** The inventive recombinant expression vectors can be designed for either transient expression, for stable expression, or for both. Also, the recombinant expression vectors can be made for constitutive expression or for inducible expression. Further, the recombinant expression vectors can be made to include a suicide gene.

**[0084]** As used herein, the term "suicide gene" refers to a gene that causes the cell expressing the suicide gene to die. The suicide gene can be a gene that confers sensitivity to an agent, e.g., a drug, upon the cell in which the gene is expressed, and causes the cell to die when the cell is contacted with or exposed to the agent. Suicide genes are known in the art (see, for example, *Suicide Gene Therapy: Methods and Reviews*, Springer, Caroline J. (Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK), Humana Press, 2004) and include, for example, the Herpes Simplex Virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase.

**[0085]** The invention further provides a host cell comprising any of the recombinant expression vectors described herein. As used herein, the term "host cell" refers to any type of cell that can contain the inventive recombinant expression vector. The host cell can be a eukaryotic cell, e.g., plant, animal, fungi, or algae, or can be a prokaryotic cell, e.g., bacteria or protozoa. The host cell can be a cultured cell or a primary cell, i.e., isolated directly from an organism, e.g., a human. The host cell can be an adherent cell or a suspended cell, i.e., a cell that grows in suspension. Suitable host cells are known in the art and include, for instance, DH5 $\alpha$  *E. coli* cells, Chinese hamster ovarian cells, monkey VERO cells, COS cells, HEK293 cells, and the like. For purposes of amplifying or replicating the recombinant expression vector, the host cell is preferably a prokaryotic cell, e.g., a DH5 $\alpha$  cell. For purposes of producing a recombinant TCR, polypeptide, or protein, the host cell is preferably a mammalian cell. Most preferably, the host cell is a human cell. While the host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage, the host cell preferably is a peripheral blood lymphocyte (PBL). More preferably, the host cell is a T cell. The T cell can be any T cell, such as any of those described herein. Preferably, the T cell is a CD8<sup>+</sup> T cell or a CD4<sup>+</sup> T cell.

**[0086]** Also provided by the invention is a population of cells comprising at least one host cell or human cell described herein. The population of cells can be a heterogeneous population comprising the human cell or host cell comprising any of the recombinant expression vectors described, in addition to at least one other cell, e.g., a host cell (e.g., a T cell), which does not comprise any of the recombinant expression vectors, or a cell other than a T cell, e.g., a B cell, a macrophage, a neutrophil, an erythrocyte, a hepatocyte, an endothelial cell, an epithelial cells, a muscle cell, a brain cell, etc. Alterna-

tively, the population of cells can be a substantially homogeneous population, in which the population comprises mainly of the inventive human cells or host cells (e.g., consisting essentially of) comprising the recombinant expression vector. The population also can be a clonal population of cells, in which all cells of the population are clones of a single human cell or host cell comprising a recombinant expression vector, such that all cells of the population are genetically identical and/or comprise the recombinant expression vector. In one embodiment of the invention, the population of cells is a clonal population comprising host cells comprising a recombinant expression vector as described herein.

**[0087]** The invention further provides an antibody, or antigen binding portion thereof, which specifically binds to a functional portion of any of the TCRs described herein, wherein the functional portion binds to amino acids 154-062 of gp100 (SEQ ID NO: 1). Preferably, the functional portion is a variable region of one of the TCRs described herein.

**[0088]** The antibody can be any type of immunoglobulin that is known in the art. For instance, the antibody can be of any isotype, e.g., IgA, IgD, IgE, IgG, IgM, etc. The antibody can be monoclonal or polyclonal. The antibody can be a naturally-occurring antibody, e.g., an antibody isolated and/or purified from a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, etc. Alternatively, the antibody can be a genetically-engineered antibody, e.g., a humanized antibody or a chimeric antibody. The antibody can be in monomeric or polymeric form. Also, the antibody can have any level of affinity or avidity for the functional portion of the inventive TCR. Desirably, the antibody is specific for the functional portion of the inventive TCR, such that there is minimal cross-reaction with other peptides or proteins.

**[0089]** Methods of testing antibodies for the ability to bind to any functional portion of the inventive TCR are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, and competitive inhibition assays (see, e.g., Janeway et al., *infra*, and U.S. Patent Application Publication No. 2002/0197266 A1).

**[0090]** Suitable methods of making antibodies are known in the art. For instance, standard hybridoma methods are described in, e.g., Köhler and Milstein, *Eur. J. Immunol.*, 5, 511-519 (1976), Harlow and Lane (eds.), *Antibodies: A Laboratory Manual*, CSH Press (1988), and C. A. Janeway et al. (eds.), *Immunobiology*, 5<sup>th</sup> Ed., Garland Publishing, New York, N.Y. (2001)). Alternatively, other methods, such as EBV-hybridoma methods (Haskard and Archer, *J. Immunol. Methods*, 74(2), 361-67 (1984), and Roder et al., *Methods Enzymol.*, 121, 140-67 (1986)), and bacteriophage vector expression systems (see, e.g., Huse et al., *Science*, 246, 1275-81 (1989)) are known in the art. Further, methods of producing antibodies in non-human animals are described in, e.g., U.S. Pat. Nos. 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication No. 2002/0197266 A1.

**[0091]** Phage display furthermore can be used to generate the antibody of the invention. In this regard, phage libraries encoding antigen-binding variable (V) domains of antibodies can be generated using standard molecular biology and recombinant DNA techniques (see, e.g., Sambrook et al. (eds.), *Molecular Cloning, A Laboratory Manual*, 3<sup>rd</sup> Edition, Cold Spring Harbor Laboratory Press, New York (2001)). Phage encoding a variable region with the desired specificity are selected for specific binding to the desired antigen, and a complete or partial antibody is reconstituted comprising the

selected variable domain. Nucleic acid sequences encoding the reconstituted antibody are introduced into a suitable cell line, such as a myeloma cell used for hybridoma production, such that antibodies having the characteristics of monoclonal antibodies are secreted by the cell (see, e.g., Janeway et al., *supra*, Huse et al., *supra*, and U.S. Pat. No. 6,265,150).

**[0092]** Antibodies can be produced by transgenic mice that are transgenic for specific heavy and light chain immunoglobulin genes. Such methods are known in the art and described in, for example U.S. Pat. Nos. 5,545,806 and 5,569,825, and Janeway et al., *supra*.

**[0093]** Methods for generating humanized antibodies are well known in the art and are described in detail in, for example, Janeway et al., *supra*, U.S. Pat. Nos. 5,225,539, 5,585,089 and 5,693,761, European Patent No. 0239400 B1, and United Kingdom Patent No. 2188638. Humanized antibodies can also be generated using the antibody resurfacing technology described in U.S. Pat. No. 5,639,641 and Pedersen et al., *J. Mol. Biol.*, 235, 959-973 (1994).

**[0094]** The invention also provides antigen binding portions of any of the antibodies described herein. The antigen binding portion can be any portion that has at least one antigen binding site, such as Fab, F(ab')<sub>2</sub>, dsFv, sFv, diabodies, and triabodies.

**[0095]** A single-chain variable region fragment (sFv) antibody fragment, which consists of a truncated Fab fragment comprising the variable (V) domain of an antibody heavy chain linked to a V domain of a light antibody chain via a synthetic peptide, can be generated using routine recombinant DNA technology techniques (see, e.g., Janeway et al., *supra*). Similarly, disulfide-stabilized variable region fragments (dsFv) can be prepared by recombinant DNA technology (see, e.g., Reiter et al., *Protein Engineering*, 7, 697-704 (1994)). Antibody fragments of the invention, however, are not limited to these exemplary types of antibody fragments.

**[0096]** Also, the antibody, or antigen binding portion thereof, can be modified to comprise a detectable label, such as, for instance, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and element particles (e.g., gold particles).

**[0097]** The invention further provides a conjugate, e.g., a bioconjugate, comprising any of the inventive human cells, TCRs, polypeptides, or proteins (including any of the functional portions or variants thereof), nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, or a combination thereof, and a therapeutic agent, a detectable moiety, or both a therapeutic agent and a detectable moiety.

**[0098]** The therapeutic agent can be any agent that yields a therapeutic effect against a disease, condition, or malady when administered to a host afflicted with the disease, condition, or malady. The disease, condition, or malady can be any disease, condition, or malady, such as an autoimmune disease, an infection (by e.g., a parasite, bacteria, or virus), or a cancer (e.g., any of the cancers described herein). Preferably, the therapeutic agent is an anti-cancer therapeutic agent. More preferably, the anti-cancer therapeutic agent is a chemotherapeutic agent, e.g., asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.

**[0099]** The detectable moiety can be any agent that can be detected through, for example, an assay, (e.g., a chemical or biophysical assay). The detectable moiety can comprise, for example, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), element particles (e.g., gold or silver particles), and the like. Such detectable moieties are known in the art.

**[0100]** Methods of synthesizing conjugates in general, are known in the art. See, for instance, Hudecz, F., *Methods Mol. Biol.* 298: 209-223 (2005) and Kirin et al., *Inorg Chem.* 44 (15): 5405-5415 (2005).

**[0101]** In a preferred embodiment of the invention, the conjugate comprises one of the inventive polypeptides or proteins described herein in a soluble form. The conjugate, for example, comprises a soluble TCR protein and a therapeutic agent and/or detectable moiety.

**[0102]** The inventive human cells, TCRs, polypeptides, proteins, (including functional portions and functional variants thereof), nucleic acids, recombinant expression vectors, host cells, populations of cells, and antibodies (including antigen binding portions thereof), can be isolated and/or purified. The term "isolated" as used herein means having been removed from its natural environment. The term "purified" as used herein means having been increased in purity, wherein "purity" is a relative term, and not to be necessarily construed as absolute purity. For example, the purity can be at least about 50%, can be greater than 60%, 70% or 80%, or can be 100%.

**[0103]** The inventive human cells, TCRs, polypeptides, proteins (including functional portions and variants thereof), nucleic acids, recombinant expression vectors, host cells populations of cells, antibodies (including antigen binding portions thereof), and conjugates, all of which are collectively referred to as "inventive TCR materials" hereinafter, can be formulated into a composition, such as a pharmaceutical composition. In this regard, the invention provides a pharmaceutical composition comprising any of the human cells, TCRs, polypeptides, proteins, functional portions, functional variants, nucleic acids, expression vectors, host cells, populations of cells, antibodies (including antigen binding portions thereof), and/or conjugates, and a pharmaceutically acceptable carrier. The inventive pharmaceutical compositions containing any of the inventive TCR materials can comprise more than one inventive TCR material, e.g., a polypeptide and a nucleic acid, or two or more different TCRs. Alternatively, the pharmaceutical composition can comprise an inventive TCR material in combination with another pharmaceutically active agents or drugs, such as a chemotherapeutic agent.

**[0104]** Preferably, the carrier is a pharmaceutically acceptable carrier. With respect to pharmaceutical compositions, the carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration. The pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active agent(s) and one which has no detrimental side effects or toxicity under the conditions of use.

**[0105]** The choice of carrier will be determined in part by the particular inventive TCR material, as well as by the particular method used to administer the inventive TCR material. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of the invention. The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, interperitoneal, rectal, and vaginal administration are exemplary and are in no way limiting. More than one route can be used to administer the inventive TCR materials, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

**[0106]** Topical formulations are well-known to those of skill in the art. Such formulations are particularly suitable in the context of the invention for application to the skin.

**[0107]** Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the inventive TCR material dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and other pharmacologically compatible excipients. Lozenge forms can comprise the inventive TCR material in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the inventive TCR material in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to, such excipients as are known in the art.

**[0108]** The inventive TCR material, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations also may be used to spray mucosa.

**[0109]** Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The inventive TCR material can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such

as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, poly(ethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.

**[0110]** Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

**[0111]** Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl- $\beta$ -aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

**[0112]** The parenteral formulations will typically contain from about 0.5% to about 25% by weight of the inventive TCR material in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more non-ionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

**[0113]** Injectable formulations are in accordance with the invention. The requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., *Pharmaceutics and Pharmacy Practice*, J. B. Lippincott Company, Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and *ASHP Handbook on Injectable Drugs*, Toissel, 4th ed., pages 622-630 (1986)). Preferably, when administering cells, e.g., human T cells, the cells are administered via injection.

**[0114]** Additionally, the inventive TCR materials, or compositions comprising such inventive TCR materials, can be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.

**[0115]** It will be appreciated by one of skill in the art that, in addition to the above-described pharmaceutical compositions, the inventive TCR materials of the invention can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.

**[0116]** For purposes of the invention, the amount or dose of the inventive TCR material administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject or animal over a reasonable time frame. For example, the dose of the inventive TCR material should be sufficient to bind to gp100, or detect, treat or prevent cancer in a period of from about 2 hours or longer, e.g., 12 to 24 or more hours, from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the efficacy of the particular inventive TCR material and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.

**[0117]** Many assays for determining an administered dose are known in the art. For purposes of the invention, an assay, which comprises comparing the extent to which target cells are lysed or IFN- $\gamma$  is secreted by T cells expressing the inventive TCR, polypeptide, or protein upon administration of a given dose of such T cells to a mammal among a set of mammals of which is each given a different dose of the T cells, could be used to determine a starting dose to be administered to a mammal. The extent to which target cells are lysed or IFN- $\gamma$  is secreted upon administration of a certain dose can be assayed by methods known in the art, including, for instance, the methods described herein as Example 1.

**[0118]** The dose of the inventive TCR material also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular inventive TCR material. Typically, the attending physician will decide the dosage of the inventive TCR material with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, inventive TCR material to be administered, route of administration, and the severity of the condition being treated. By way of example and not intending to limit the invention, the dose of the inventive TCR material can be about 0.001 to about 1000 mg/kg body weight of the subject being treated/day, from about 0.01 to about 10 mg/kg body weight/day, about 0.01 mg to about 1 mg/kg body weight/day.

**[0119]** One of ordinary skill in the art will readily appreciate that the inventive TCR materials of the invention can be modified in any number of ways, such that the therapeutic or prophylactic efficacy of the inventive TCR materials is increased through the modification. For instance, the inventive TCR materials can be conjugated either directly or indirectly through a linker to a targeting moiety. The practice of conjugating compounds, e.g., inventive TCR materials, to targeting moieties is known in the art. See, for instance, Wadwa et al., *J. Drug Targeting* 3: 111 (1995) and U.S. Pat. No. 5,087,616. The term "targeting moiety" as used herein, refers to any molecule or agent that specifically recognizes and binds to a cell-surface receptor, such that the targeting moiety directs the delivery of the inventive TCR materials to a population of cells on which surface the receptor is expressed. Targeting moieties include, but are not limited to, antibodies, or fragments thereof, peptides, hormones, growth factors, cytokines, and any other natural or non-natural ligands, which bind to cell surface receptors (e.g., Epithelial Growth Factor Receptor (EGFR), T-cell receptor (TCR),

B-cell receptor (BCR), CD28, Platelet-derived Growth Factor Receptor (PDGF), nicotinic acetylcholine receptor (nAChR), etc.). The term “linker” as used herein, refers to any agent or molecule that bridges the inventive TCR materials to the targeting moiety. One of ordinary skill in the art recognizes that sites on the inventive TCR materials, which are not necessary for the function of the inventive TCR materials, are ideal sites for attaching a linker and/or a targeting moiety, provided that the linker and/or targeting moiety, once attached to the inventive TCR materials, do(es) not interfere with the function of the inventive TCR materials, i.e., the ability to bind to a cancer antigen, or to detect, treat, or prevent cancer.

**[0120]** Alternatively, the inventive TCR materials can be modified into a depot form, such that the manner in which the inventive TCR materials is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Pat. No. 4,450,150). Depot forms of inventive TCR materials can be, for example, an implantable composition comprising the inventive TCR materials and a porous or non-porous material, such as a polymer, wherein the inventive TCR materials is encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body and the inventive TCR materials are released from the implant at a predetermined rate.

**[0121]** It is contemplated that the inventive pharmaceutical compositions comprising any of the inventive human cells, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, or conjugates can be used in methods of treating or preventing cancer. Without being bound to a particular theory, the inventive TCRs are believed to bind specifically to gp100, e.g., gp100<sub>154-162</sub>, such that the TCR (or related inventive polypeptide or protein) when expressed by a cell is able to mediate an immune response against the cell expressing gp100. As mentioned herein, gp100 is expressed on the surface of tumor cells. In this regard, the invention provides a method of treating or preventing cancer in a host, comprising administering to the host any of the pharmaceutical compositions described herein in an amount effective to treat or prevent cancer in the host.

**[0122]** The terms “treat,” and “prevent” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the inventive methods can provide any amount of any level of treatment or prevention of cancer in a mammal. Furthermore, the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or symptoms of the disease, e.g., cancer, being treated or prevented. Also, for purposes herein, “prevention” can encompass delaying the onset of the disease, or a symptom or condition thereof.

**[0123]** Also provided is a method of detecting the presence of cancer in a host. The method comprises (i) contacting a sample comprising cells of the cancer any of the inventive human cells, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, or conjugates described herein, thereby forming a complex, and detecting the complex, wherein detection of the complex is indicative of the presence of cancer in the host.

**[0124]** With respect to the inventive method of detecting cancer in a host, the sample of cells of the cancer can be a sample comprising whole cells, lysates thereof, or a fraction of the whole cell lysates, e.g., a nuclear or cytoplasmic fraction, a whole protein fraction, or a nucleic acid fraction.

**[0125]** For purposes of the inventive detecting method, the contacting step can take place in vitro or in vivo with respect to the host. Preferably, the contacting is in vitro.

**[0126]** Also, detection of the complex can occur through any number of ways known in the art. For instance, the inventive human cells, TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, or antibodies, or antigen binding portions thereof, described herein, can be labeled with a detectable label such as, for instance, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and element particles (e.g., gold particles).

**[0127]** For purposes of the inventive methods, wherein human cells, host cells, or populations of cells are administered, the cells can be cells that are allogeneic or autologous to the host. Preferably, the cells are autologous to the host.

**[0128]** With respect to the inventive methods, the cancer can be any cancer, including any of acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, and urinary bladder cancer. Preferably, the cancer is colorectal cancer or melanoma.

**[0129]** The host referred to in the inventive methods can be any host. Preferably, the host is a mammal. As used herein, the term “mammal” refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perissodactyla, including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboidea, or Simiiformes (monkeys) or of the order Anthropoidea (humans and apes). An especially preferred mammal is the human.

**[0130]** The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

#### Example 1

**[0131]** This example demonstrates a method of obtaining a murine TCR reactive with a human gp100 epitope.

**[0132]** The first part of the method comprises immunizing HLA-A\*0201 (A2.1) transgenic mice with human gp100 peptide and then functionally assaying the bulk cultures of splenocytes obtained therefrom.

**[0133]** HLA-A\*0201 (A2.1) transgenic mice were immunized with 100 µg of the gp100<sub>154-162</sub> peptide (KTWGQY-WQV; SEQ ID NO: 34) and 120 µg of the I-Ab-binding synthetic T helper peptide representing residues 128-140 of the hepatitis B virus core protein (HBV-Core) emulsified in incomplete Freund's adjuvant. The mice were re-immunized with the same dose of antigens emulsified in incomplete Freund's adjuvant seven days after the first immunization. Spleens of the immunized mice were harvested one week after the second immunization.

**[0134]** HLA-A2 transgenic mouse splenocytes (from un-immunized mice) were irradiated (irradiated with 3000 rads), activated with lipopolysaccharide (LPS), and pulsed with 0.01 µg/ml of gp100<sub>154-162</sub> peptide and 10 µg/ml of human β2-microglobulin. Splenocytes (3×10<sup>6</sup>) were stimulated in 24 well-plate culture (RPMI 1640, with 10% of fetal bovine serum (FBS)) with an equal number of the irradiated, activated, and pulsed splenocytes. The splenocytes from the immunized mice were stimulated in this manner every 7-10 days with the addition of 10 CU/ml of IL-2 added to the culture media. Eight days after the third re-stimulation, the cells were tested for antigen recognition and gp100<sub>154-162</sub> tetramer binding.

**[0135]** To test whether the TCRs of the cells recognized antigen, T cells (1×10<sup>5</sup>) were cultured with equal number of target cells (T2 cells pulsed with the gp100<sub>154-162</sub> peptide or human melanoma cells expressing gp100 (Mel526)) or negative control cells (human gp100-negative melanoma cells (MelA375) or T2 cells pulsed with an irrelevant peptide (β-gal)). Antigen recognition by the T cells was indicated by the amount of IFN-γ secreted by the T cells, which was measured by ELISA using the ENDOGEN® Human IFNγ Colorimetric ELISA according to the manufacturer's instructions.

**[0136]** As shown in FIG. 1, T cells from HLA-A2 mice immunized with gp100<sub>154-162</sub> peptide recognized T2 cells pulsed with as little as 1 nM gp100<sub>154-162</sub> peptide and also recognized gp100-expressing Mel526 cells.

**[0137]** To test whether the TCRs of the cells could bind to gp100<sub>154-162</sub> tetramers, T cells were labeled with anti-mouse CD8-FITC mAb and gp100<sub>154-162</sub>-HLA-A2 tetramer or a negative control tetramer (gp100<sub>209-217</sub>-HLA-A2 tetramers). To verify that the negative control was properly working, human gp100<sub>209-217</sub>-specific T cell clones were labeled with anti-human CD8-fluorescein isothiocyanate (FITC) mAb and gp100<sub>209-217</sub>-HLA-A2 tetramers. Tetramer binding was measured by flow cytometry, as the tetramers were labeled with PE.

**[0138]** As shown in FIG. 2, T cells from HLA-A2 mice immunized with gp100<sub>154-162</sub> bound to gp100<sub>154-162</sub> tetramers and not to the negative control tetramers (gp100<sub>209-217</sub> tetramers).

**[0139]** Collectively, FIGS. 1 and 2 suggest that the bulk culture of splenocytes from gp100<sub>154-162</sub>-immunized transgenic mice contained T cells with TCRs specific for gp100<sub>154-162</sub>. The next part of the method comprised isolating T cell clones having activity against gp100<sub>154-162</sub> from the bulk culture.

**[0140]** T cells from the bulk culture were plated in 96-well round bottom plates at 0.3, 1, 3, or 10 cells/well in 100 µL media additionally containing 10 CU/ml of IL-2, 5×10<sup>4</sup> irradiated T2 cells (irradiated at 20,000 rads) pulsed with gp100<sub>154-162</sub> peptide (0.01 µg/ml), and 2-3×10<sup>5</sup> irradiated C57BL6 splenocytes (irradiated at 3000 rads). Within a year, 29 clones, including a single clone (clone Sp(0.01)A) were tested for antigen recognition and tetramer binding.

**[0141]** To test whether the TCRs of the cells recognized antigen, the T cells of individual wells were assayed as essentially described above. Briefly, T cells (1×10<sup>5</sup>) were cultured with an equal number of target cells (gp100<sub>154-162</sub> peptide-pulsed T2 cells or human melanoma cells expressing gp100 (Mel526)) or negative control cells (human gp100-negative melanoma cells (MelA375) or T2 cells pulsed with irrelevant peptide (gp100<sub>209-217(m)</sub> peptide). Antigen recognition by the T cells were measured by carrying out ELISAs which assayed the amount of IFN-γ secreted by the T cells.

**[0142]** As shown in FIG. 3, clone Sp(0.01)A recognized the gp100<sub>154-162</sub> peptide and Mel 526 cells.

**[0143]** To test for tetramer binding, the T cells of individual wells were labeled as described above. Briefly, T cells were labeled with anti-mouse CD8-FITC mAb and gp100<sub>154-162</sub>-HLA-A2 tetramer or with a negative control tetramer (gp100<sub>209-217</sub>-HLA-A2 tetramer). To verify that the negative control was working, human T cell clones specific for gp100<sub>209-217</sub> peptide were labeled with anti-human CD8-FITC mAb and gp100<sub>209-217</sub>-HLA-A2 tetramer. Flow cytometry was subsequently carried out to measure the tetramer binding.

**[0144]** As shown in FIG. 4, T cells of clone Sp(0.01)A bound to the gp100<sub>154-162</sub> tetramer and not the gp100<sub>209-217</sub> tetramer.

**[0145]** FIGS. 3 and 4 collectively suggest that the T cell clone Sp(0.01)A comprises a TCR which is specific to the gp100<sub>154-162</sub> peptide. The molecular cloning of the TCR of this clone was subsequently carried out.

**[0146]** Total RNA from Sp(0.01)A T cell clones was isolated using Qiagen RNeasy Mini Kit cDNA and was prepared using Clontech SMART™ RACE cDNA Amplification kit. 5' RACE was performed using Clontech SMART™ RACE kit and TCR gene-specific primers derived from the constant region of the mouse TCR α and β chains (3' TCRAC ggc-tacttcagcaggagga (SEQ ID NO: 36) and 3' TCRBC aggctct-gcactgatgttc (SEQ ID NO: 37)). The forward primers were Universal Primer mix for 5' end RACE from Clontech. The RACE products were then ligated into pcDNA3.1/V5-His Topo TA cloning vector, and transformed into Top 10 bacteria. The transformed bacteria were plated onto ampicillin (Amp)-containing LB plates. Twenty-four colonies for each chain were selected and individually cultured in 1.2 ml of Amp-containing LB for plasmid DNA preparation. Plasmid DNA was isolated and sequenced using the following primers: 3' TCRACseq actggtacacagcagggtctgg (SEQ ID NO: 38) and 3' TCRBCseq aaggagaccttgggtggagtc (SEQ ID NO: 39) to determine the 5' gene specific primer. Full length TCR were then PCRd from 5' RACE ready cDNA using the primers 5'TRA7D3\*01: caccatgaatccttgagtgttcc (SEQ ID NO: 40) and 3' TCRA: tcaactggaccacagcctcagc (SEQ ID NO: 41) for the α chain.

**[0147]** For the β chain, PCRs were first performed using the primers: 5'TRB13-3\*01: caccatggctccagactctcttt (SEQ ID NO: 42) and 3' TCRBC: aggctctgcactgatgttc (SEQ ID NO: 43), 5' TCRBCseqreverse: aaggagaccttgggtggagtc (SEQ ID NO: 44), and 3' TCRB: tcataattcttctttgaccatagcc (SEQ ID NO: 45). The two PCR fragments were linked together using PCR with primers 5'TRB13-3\*01: caccatggctccagactctcttt (SEQ ID NO: 46) and 3' TCRB: tcataattcttctttgaccatagcc (SEQ ID NO: 47). Advantagess® HF 2 Taq polymerase was the polymerase used in cloning the full length cDNA of each chain of the TCR. For each PCR, the reaction conditions were as follows: 95° C. for 1 minute, 35 cycles of 95° C. for 30 sec



## Example 3

**[0164]** This example demonstrates the frequency of variable regions amongst the gp100<sub>154-162</sub>-specific clones.

**[0165]** As mentioned in Example 1, 29 T cell clones were isolated from the bulk culture of which one was Sp(0.01)A. The TCRs of the other 28 clones were sequenced as essentially described in Example 1, and the sequences were compared to those published in the online IMGT/V-Quest database. The frequency of the alpha and beta variable regions from each clone is shown in Table 1.

TABLE 1

Clone Name	TCR chain	Name of variable region	Frequency
T2(1)C	alpha	TRAV10*02	11/12
	alpha	TRAV4D-4*03	1/12
	beta	TRBV12-2*01	14/14
Sp(0.01)A	alpha	TRAV7D-3*01	14/15
	alpha	TRAV6D-6*02	1/15
	beta	TRBV13-3*01	7/7
T2(1)A	alpha	TRAV7D-3*01	14/22
	alpha	TRAV6D-6*02	8/22
	beta	TRBV13-1*02	10/22
T2(1)B	beta	TRBV4*01	12/22
	alpha	TRAV10*02	17/19
	alpha	TRAV4D-4*03	2/19
T2(1)K	beta	TRBV12-2*01	19/19
	alpha	TRAV10*02	14/16
	alpha	TRAV4D-4*03	2/16
Sp(0.1)A10	beta	TRBV12-2*01	21/21
	alpha	TRAV9D-3*02	15/21
	alpha	TRAV6D-5*01	6/21
T2(1)J	beta	TRBV12-2*01	17/17
	alpha	TRAV10*02	6/6
	beta	TRBV12-2*01	17/17
T2(1)N	alpha	TRAV10*02	12/21
	alpha	TRAV16*05	9/21
	beta	TRBV12-2*01	19/19
T2(1)H	alpha	TRAV3-3*02	14/16
	alpha	TRAV10*02	2/16
	beta	TRBV19*01	15/22
T2(1)P	beta	TRBV12-2*01	5/22
	beta	TRBV13-3*01	1/22
	beta	TRBV5*01	1/22
T2(1)G	alpha	TRAV10*02	17/18
	alpha	TRAV4D-4*03	1/18
	beta	TRBV12-2*01	11/12
Sp(0.01)B	beta	TRBV12-2*02	1/12
	alpha	TRAV7D-3*01	12/14
	alpha	TRAV6D-6*02	2/14
Sp(0.01)C	beta	TRBV13-3*01	14/15
	beta	TRBV19*01	1/15
	alpha	TRAV13D-2*01	20/20
Sp(1)A	beta	TRBV31*01	19/19
	alpha	TRAV6D-3*01	17/21
	alpha	TRAV13-2*02	4/21
T2(1)M	beta	TRBV5*01	22/22
	alpha	TRAV10*02	17/18
	alpha	TRAV4D-4*03	1/18
T2(1)O	beta	TRBV12-2*01	13/13
	alpha	TRAV13D-2*01	14/17
	alpha	TRAV4D-4*03	1/17
T2(1)Q	alpha	TRAV10*02	1/17
	alpha	TRAV7D-3*01	1/17
	beta	TRBV13*01	14/22
T2(1)R	beta	TRBV5*01	1/22
	beta	TRBV12-2*01	7/22
	alpha	TRAV9D-4*02	7/17
T2(1)S	alpha	TRAV7D-3*01	10/17
	beta	TRBV1*01	23/23
	alpha	TRAV10*02	17/22
T2(1)T	alpha	TRAV7D-3*01	1/22
	alpha	TRAV13D-2*01	4/22
	beta	TRBV12-2*01	17/17

TABLE 1-continued

Clone Name	TCR chain	Name of variable region	Frequency
T2(1)T	alpha	TRAV13D-2*01	16/16
	beta	TRBV12-2*01	9/21
	beta	TRBV1*01	4/21
	beta	TRBV31*01	7/21
	beta	TRBV5*01	1/21
T2(1)Cpost	alpha	TRAV10*02	20/23
	alpha	TRAV4D-4*04	3/23
	beta	TRBV12-2*01	18/18
T2(0.01)A	alpha	TRAV6-7/DV9*06	3/7
	alpha	TRAV4D-4*03	4/7
	beta	TRBV13-3*01	11/11
Sp(0.01)K	alpha	TRAV7D-3*01	16/22
	alpha	TRAV6-7/DV9*06	6/22
Sp(0.01)D	beta	TRBV13-3*01	23/23
	alpha	TRAV8-1*01	3/4
T2(1)S	beta	TRBV13-3*01	5/5
	alpha	TRAV10*02	15/17
Sp(5)B	alpha	TRAV4D-4*03	2/17
	beta	TRBV12-2*01	8/8
	alpha	TRAV6-7/DV9*06	20/20
T2(1)U	beta	TRBV12-2*01	1/16
	beta	match genbank AY499163	15/16
	alpha	TRAV8-1*01	18/20
T2(1)I	alpha	TRAV7D-2*-3	1/20
	alpha	TRAV12D-2*02	1/20
	beta	TRBV3*01	7/7
T2(1)L	alpha	TRAV13D-3*01	2/17
	alpha	TRAV10*02	12/14
	beta	TRBV12-2*01	8/8
T2(1)R	alpha	TRAV10*02	17/19
	alpha	TRAV4D-4*03	2/19
	beta	TRBV12-2*01	15/15
Sp(1)B	alpha	TRAV8-1*01	1/9
	alpha	TRAV10*02	4/9
	alpha	TRAV7D-3*01	3/7
	alpha	TRAV12D-2*02	1/9
	beta	TRBV1*01	11/11
T2(1)Q	alpha	TRAV6-7/DV9*06	1/5
	alpha	TRAV4D-4*03	1/5
	alpha	TRAV10*02	2/5
T2(1)H	alpha	TRAV8-a*01	1/5
	beta	unknown	

**[0166]** This example demonstrated the frequency of the variable regions of each of the chains of the TCRs expressed by the gp100<sub>154-162</sub>-specific clones.

## Example 4

**[0167]** This example demonstrates the activity of other murine TCRs specific for gp100.

**[0168]** Human PBLs ( $1 \times 10^6$ ) were electroporated with 2  $\mu$ g RNA encoding each of the alpha and beta chains of the TCRs of clones Sp(0.01)A, T2(1)B, Sp(0.1)A10, and T2(1)C as essentially described in Example 2. The nucleotide sequences encoding each of the alpha and beta chains of the TCRs from clones T2(1)B, Sp(0.1)A10, and T2(1)C are shown in FIGS. 10A-C, respectively. The cells were then tested for tetramer binding and antigen recognition against T2 cells pulsed with varying amounts of gp100<sub>154-162</sub>. For tetramer binding, the electroporated cells were stained with PE-linked HLA-A2/gp100<sub>154-162</sub> tetramer and with FITC-linked anti-murine TCR beta chain antibody (Vb) 24 hours post-transfection. Tetramer and antibody binding was measured by flow cytometry as described in Example 2. Table 2 indicates the percentage per percentage of mouse beta chain positive cells.

TABLE 2

Clone Name	% tetramer positive cells
Sp(0.01)A	100%
T2(1)B	13%
Sp(0.1)A10	10%
T2(1)C	Undetectable

**[0169]** The electroporated human PBLs were co-cultured overnight with gp100<sub>154-162</sub> peptide-pulsed T2 cells and the concentration of IFN- $\gamma$  in the supernatant was subsequently measured by ELISA. Table 3 indicates the lowest gp100<sub>154-162</sub> peptide concentration that was specifically recognized by the electroporated human PBLs.

TABLE 3

Clone Name	Minimal concentration
Sp(0.01)A	<10 <sup>-10</sup> M
T2(1)B	10 <sup>-9</sup> -10 <sup>-10</sup> M
Sp(0.1)A10	10 <sup>-9</sup> M
T2(1)C	10 <sup>-6</sup> M

**[0170]** Purified human CD8<sup>+</sup> T cells were electroporated with RNA encoding TCRs from clones Sp(0.01)A, T2(1)B, Sp(0.1)A10, and T2(1) C) and co-cultured overnight with HLA-A2<sup>+</sup>/hgp100<sup>+</sup> human melanoma cells (624, 526 and SK23). The concentration of IFN- $\gamma$  in the supernatant was subsequently measured by ELISA. Table 4 indicates the relative levels of IFN- $\gamma$  produced by the electroporated cells. Each plus sign indicates at least one log(10 times) increase in IFN- $\gamma$  production.

TABLE 4

Clone Name	Tumor reactivity in human CD8 <sup>+</sup> T cells
Sp(0.01)A	+++
T2(1)B	++/+++
Sp(0.1)A10	+
T2(1)C	Undetectable

**[0171]** Purified human CD4<sup>+</sup> T cells were electroporated with RNA encoding the TCRs of clones Sp(0.01)A, T2(1)B, Sp(0.1)A10, and T2(1)C and co-cultured overnight with HLA-A2<sup>+</sup>/hgp100<sup>+</sup> human melanoma cells (624, 526 and SK23). The concentration of IFN- $\gamma$  in the supernatant was measured by ELISA. Table 5 indicates the relative levels of IFN- $\gamma$  produced by the electroporated cells. Each plus sign indicates at least one log(10 times) increase in IFN- $\gamma$  production.

TABLE 5

Clone Name	Tumor reactivity in human CD4 <sup>+</sup> T cells
Sp(0.01)A	+++
T2(1)B	-
Sp(0.1)A10	-
T2(1)C	Undetectable

**[0172]** Based on the above results, the TCR of clone Sp(0.01)A demonstrated the highest avidity for gp100<sub>154-162</sub>, whereas the avidities of the TCRs of clones T2(1)B and Sp(0.1)A10 was intermediate, while the avidity of the TCR of clone T2(1)C was the lowest.

**[0173]** This example demonstrated other murine TCRs that are specific for the gp100<sub>154-162</sub> epitope.

## Example 5

**[0174]** This example demonstrates the relative activities of tumor antigen specific TCRs.

**[0175]** Human PBL were electroporated with RNAs encoding either hgp100<sub>154-162</sub>-specific human TCRs or mouse TCR (Sp0.01A). RNA expression was measured by tetramer binding as assessed by FACS. The activity of the PBL expressing the TCRs were compared via an IFN- $\gamma$  release assay. The results are shown in Table 6.

TABLE 6

Assay	Human TCR 1	Human TCR 2	Human TCR 3	Sp0.01A	
<sup>154-162</sup> Tetramer binding (%)	1	6	4	95	
IFN- $\gamma$ release (pg/ml)					
HLA-A2 <sup>+</sup> , hgp100 <sup>+</sup> melanoma	Mel 526 SK 23 Mel 624	11 11 16	894 944 622	41 108 41	20533 43346 37562
HLA-A2 <sup>-</sup> , hgp100 <sup>-</sup> melanoma	Mel 938 Meal 888	21 38	5 9	15 0	6 13
HLA-A2+, hgp100- melanoma	A 375	56	45	37	45

**[0176]** As shown in Table 6, the activity of PBL expressing the Sp0.01A mouse gp100 specific TCR was dramatically higher than the human gp100 specific TCR.

**[0177]** The relative avidities of the mouse gp100-specific TCR (Mo h154 TCR) and human MART TCR (Hu Mart1 TCR (F4)) were also compared. As shown in FIG. 11, the mouse 154 TCR exhibited 10-100 fold greater recognition of tumor antigens as measured by an ex vivo cytokine release assay. This was observed for both pulsed targets (FIG. 11, left panel) and cultured human tumor cell lines (FIG. 11, right panel).

**[0178]** Additionally, a single transduction with recombinant retrovirus encoding the Sp0.01A TCR (the TCR from the most highly avid mouse T cell line) yielded approximately 90% of the human PBL expressing the hgp100<sub>154-162</sub>-specific TCR. As shown in Table 7, these cells were able to specifically produce IFN- $\gamma$  upon co-culture with human melanoma cell lines expressing the target antigen (gp100) and the appropriate restriction element (HLA-A2).

TABLE 7

Assay	Untransduced	Transduced	
<sup>154-162</sup> Tetramer binding (%)	1	88	
IFN- $\gamma$ release (pg/ml)			
HLA-A2 <sup>+</sup> , hgp100 <sup>+</sup> melanoma	Mel 526 SK 23 Mel 624	2 4 12	18523 48044 22811
HLA-A2 <sup>-</sup> , hgp100 <sup>-</sup> melanoma	Mel 938 Meal 888	21 38	22 0
HLA-A2+, hgp100- melanoma	A 375	56	31

**[0179]** PBLs were retrovirally transduced with a gp100: 154-162-specific TCR, DMF4 MART-1 specific TCR, DMF5 MART-1 specific TCR, mDMF5 MART-1 specific TCR, or

control vector (GFP). Cytolytic activity of the PBL were then assayed by a standard chromium release assay. As shown in FIG. 12, the DMF5 and gp154 TCRs provided the highest recognition of HLA-A2 expressing melanomas than the other TCRs.

**[0180]** The potential for crossreactivity of the murine anti-gp100 TCR with normal cells was tested using human PBL transduced with the retroviral vector expressing the anti-gp100(154)TCR ( $1 \times 10^5$ ), which were co-cultured with test cell lines ( $1 \times 10^5$  cells). Twenty-four hours after co-culture, the concentration (pg/mL) of IFN- $\gamma$  secreted in the medium was measured by ELISA. Only melanoma tumor cell lines were recognized by patient cells transduced with anti-gp100 (154) retroviral vector.

**[0181]** This example demonstrated the relative activities of a TCR of the invention.

#### Example 6

**[0182]** This example demonstrates a method of preparing cells for infusion, in accordance with the invention.

**[0183]** The following materials were used in the method: Ca++-Mg++-, Phenol red-free Hanks' balanced salt solution (HBSS) (BioWhittaker); RPMI 1640 with L-Glutamine (BioWhittaker); HEPES, 1M pH 7.0, stock (BioWhittaker); 2-Mercaptoethanol,  $5.5 \times 10^{-2}$ M in D-PBS, stock (GIBCO BRL); Penicillin G sodium (10,000 units/ml), streptomycin (10,000 mg/ml) stock (BioWhittaker); Gentamycin (50 mg/ml) stock (BioWhittaker); Ciprofloxacin (Cipro 1% solution, Bayer); Fungizone (250 mcg/ml stock; Bristol-Myers Squibb); AIM V serum free lymphocyte growth medium (GIBCO BRL); X-VIVO 20 serum free lymphocyte growth medium (BioWhittaker); 0.9% sodium chloride, USP (Baxter); Human Serum, type AB (Valley Biomedical); Human PBMC; Human albumin (Plasbumin-25, Bayer); Recombinant human IL-2 ( $10^6$  CU/ml) (Cetus Oncology Div, Chiron, wherein 50 Cetus units (CU)=300 International units (IU)); OKT3 (Ortho-anti-CD3) (Orthoclone); gp100 peptide 1.0 mg/ml stock; Lymphocyte separation medium (LSM) (ICN); Plastic pipettes, 2, 5, 10, 25, and 50 ml; Pipette tips, 200  $\mu$ l and 1 ml; 96-well tissue culture plates, flat-bottom and U-bottom (Costar); 6 and 24 well non-tissue culture treated plates, (Falcon); Tissue culture flasks, vented cap, 25 and 175 cm<sup>2</sup> (Costar Corp); Centrifuge tubes, 15, 50 and 250 ml (Corning); Sampling site coupler (Baxter/Fenwal, Deerfield, Ill.); Solution transfer set (Baxter/Fenwal); Lifecell adapter set (Baxter/Fenwal); Interconnecting jumper tube, 8" (GIBCO); Solution transfer pump (Baxter/Fenwal); Culture bags, PL732 1 liter (Baxter/Fenwal); Culture bags, PL732 3 liter (Baxter/Fenwal); TCR retroviral vectors (GCsamAPB and MSGV1AIB, National Gene Vector Laboratory, Indiana University); Antibody to murine TCR  $\beta$  chain (Bb Biosciences); QuickExtract™ DNA extraction solution 1.0. (Epicentre); First-strand cDNA synthesis Kit (Amersham Pharmacia biotech); STRATAGENE Absolutely RNA™ RT-PCR Miniprep Kit (STRATAGENE). All materials in contact with cells or their media are supplied sterile.

**[0184]** Peripheral blood lymphocytes (PBL) were stimulated, transduced, and reinfused in a similar fashion to previously approved clinical protocols. Briefly, PBL were isolated by leukopheresis. Lymphocytes were separated by centrifugation on a Ficoll-Hypaque cushion, washed in HBSS, then resuspended at a concentration of  $1 \times 10^6$ /ml in lymphocyte growth medium supplemented with 50 ng/ml OKT3, 300 IU/ml IL-2, and 5% human AB serum. If patients had a history of antibiotic allergy, the antibiotic was not used in the culture medium. After 2 days of culture, cells were collected, resuspended in fresh medium without OKT3, and plated onto

tissue cultured plates that had been pre-coated with Retronectin and the TCR retroviral vectors, and transduction accomplished as follows.

**[0185]** All transductions were performed in the wells of 6-well plates. Wells were precoated with Retronectin followed by TCR retroviral vector. Retronectin, a recombinant chimeric fibronectin molecule, has been approved by FDA to be used in other clinical trials involving transduction of genes into human hematopoietic cells. The clinical GMP grade Retronectin was supplied by Takara Biomedicals, Japan. Retronectin was coated as follows: 2 mls of  $1 \times$ PBS containing 50  $\mu$ g/ml retronectin was placed in each well of 6-well plate at 4° C. overnight or at room temperature for 2 hours. Wells were blocked with 2 mls of 1% human albumin in  $1 \times$ PBS at room temperature for 30 minutes and washed once with 2 mls of  $1 \times$ PBS containing 2.5% HEPES, pH 7.0 (v/v). 6-12 mls of TCR retroviral supernatant were applied to each retronectin-coated well and incubated at 32° C. for 2 hours followed by 12-48 hours at 4° C. Retroviral supernatant was removed and up to  $5 \times 10^6$  PBL cells in lymphocyte growth medium supplemented with 300 IU/ml IL-2, and 5% human AB serum was applied onto retronectin and retroviral vector coated wells. The culture was incubated at 37° C., 5% CO<sub>2</sub> incubator overnight.

**[0186]** The following day, the PBL were transferred to a second set of pre-coated retronectin retroviral vector tissue culture plates. Two days after the last transduction, the PBL cultures were assayed for the presence of the appropriate murine TCR  $\beta$  chain protein and for activity. Cells ( $1 \times 10^6$ ) transduced with the gp100:154-162 TCR vector were stained with antibody for the murine TCR  $\beta$  chain protein, followed by analysis by FACS. Transduction was considered successful if >10% of the PBL were positive for the murine TCR  $\beta$  chain protein. To test for anti-tumor activity,  $1 \times 10^5$  transduced PBL were coincubated with  $1 \times 10^5$  target cells. Target cells were T2 cells pulsed with 1.0 microgram/ml gp100 peptide, and a control (Flu) peptide. After 24 hours of incubation, supernatants were harvested and IFN- $\gamma$  quantified by ELISA capture assay. The transduced cultures that released >200 pg/ml of IFN- $\gamma$  (and 4 $\times$  background levels produced in control incubations) were considered biologically active.

**[0187]** At the end of transduction, cells were washed and maintained in lymphocyte growth medium supplemented with 300 U/ml IL-2, and 5% human AB serum and maintained at a density of  $1 \times 10^6$  cells/ml. The cultures were incubated at 37° C., 5% CO<sub>2</sub> incubator until infusion. If cells had grown to sufficient numbers for patient treatment, a sample was collected for sterility before the beginning of PBL therapy.

**[0188]** A sample of TCR transduced PBL cells was collected 3 days prior to infusion and tested for replication-competent retrovirus (RCR) contamination by GALV envelope gene-PCR and S<sup>+</sup>/L<sup>-</sup> assays to test replication-competent retrovirus (RCR) according to published methods (Chen et al., *Human Gene Ther.* 12: 61-70 (2001)). Samples for S<sup>+</sup>/L<sup>-</sup> will be sent to National Gene Vector Laboratory (NGVL, Indiana University) for analysis. PCR results (positive or negative) were available prior to the infusion of PBL cells. Definitive S<sup>+</sup>/L<sup>-</sup> assay results were not available prior to cell infusion.

**[0189]** On days 14-20, the final product was prepared for patient infusion. The contents (cells and media) of flasks were transferred to 250 ml centrifuge tubes, while cells in Baxter culture bags were harvested using a Baxter/Fenwal continu-

ous centrifuge cell harvester system. Aliquots were taken from representative bags and pooled for a gram test. Cells were spun to pellet (1000 rpm, 15 min, R/T) and combined in a single tube, then washed by resuspension in 0.9% sodium chloride followed by centrifugation, and finally resuspended in 45-400 ml of 0.9% sodium chloride. Human albumin (25%) was added to a final concentration of 2.5%. Aliquots were removed for cell count and viability testing by trypan blue exclusion, and for QC testing. The final product was then ready for infusion.

#### Example 7

**[0190]** This example demonstrates a method of administering to humans cells expressing a TCR of the invention.

**[0191]** PBMC were obtained by leukapheresis (approximately  $5 \times 10^9$  cells). Whole PBMC were cultured in the presence of anti-CD3 (OKT3) and aldesleukin in order to stimulate T-cell growth according to Example 6. Transduction was initiated by exposure of approximately  $10^8$  to  $5 \times 10^8$  cells to supernatant containing the anti-gp100:154-162 TCR retroviral vector. These transduced cells were expanded and tested for their anti-tumor activity. Each culture's growth characteristics and transduction efficiency could not be predicted in advance; some cultures grew better than others, and gene transfer efficiency varied from patient to patient. Successful TCR gene transfer was determined by FACS analysis for the TCR protein and anti-tumor reactivity was tested by cytokine release as measured on peptide pulsed T2 cells. Successful TCR gene transfer for each transduced PBL population was defined as >10% murine TCR positive cells and for biological activity, gamma-interferon secretion must be at least 200 pg/ml. Patients received up to  $3 \times 10^{11}$  anti-gp 100: 154-162 TCR engineered PBL. A minimum of approximately  $5 \times 10^8$  cells was given. In prior protocols, over  $3 \times 10^{11}$  T cells have been safely infused to cancer patients.

**[0192]** Patients received a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed in one to four days by intravenous infusion of in vitro tumor reactive, TCR gene-transduced PBL plus IV aldesleukin (720,000 IU/kg q8h for a maximum of 15 doses). Approximately 2 hours prior to cell infusion and 14 days later, patients received the subcutaneous (S.C.) injection of ALVAC (2) gp100(M)/MAGE-1,3 minigene/TRICOM (vcP2292). A two week safety assessment period followed regimen completion for each of the first three patients before subsequent patients were accrued in the initial phase of this study.

**[0193]** The protocol for drug administration was as follows:

**[0194]** On Day -7 and -6 at 1 am:

**[0195]** Hydrate: Begin hydration with 0.9% Sodium Chloride Injection containing 10 meq/L of potassium chloride at 2.6 ml/kg/hr (starting 11 hours pre-cyclophosphamide and continue hydration until 24 hours after last cyclophosphamide infusion).

**[0196]** On Day -7 and -6 at 1 am:

**[0197]** (1) Ondansetron (0.15 mg/kg/dose [rounded to the nearest even mg dose between 8 mg and 16 mg based on patient weight] IV every 8 hours x3 days) will be given for nausea.

**[0198]** (2) Furosemide 20 mg iv.

**[0199]** On Day -7 and -6 at 12 pm (noon):

**[0200]** Cyclophosphamide 60 mg/kg/day x2 days IV in 250 ml D5W with mesna 15 mg/kg/day x2 days over 1 hr. If patient is obese (BMI>35) drug dosage will be calculated using practical weight as described in Table 13.

**[0201]** On Day -7 and -6 at 1 pm:

**[0202]** Begin to monitor potassium level every 12 hours until hydration is stopped. KCl will be adjusted to maintain serum potassium levels in the normal range.

**[0203]** Begin mesna infusion at 3 mg/kg/hour intravenously diluted in a suitable diluent (see pharmaceutical section) over 23 hours after each cyclophosphamide dose. If patient is obese (BMI>35) drug dosage will be calculated.

**[0204]** On Day -5:

**[0205]** Stop IV hydration (24 hours after last cyclophosphamide dose). If urine output <1.5 ml/kg/hr give additional 20 mg furosemide iv. If body weight >2 kg over pre cyclophosphamide value give additional furosemide 20 mg iv.

**[0206]** On Day -5 to Day -1:

**[0207]** Fludarabine 25 mg/m<sup>2</sup>/day IVPB daily over 30 minutes for 5 days. If patient is obese (BMI>35) drug dosage will be calculated.

**[0208]** Cells prepared as detailed in Example 6 were delivered to the patient care unit by a staff member from the Tumor Immunology Cell Processing Laboratory. Prior to infusion, the cell product identity label was double-checked by two authorized staff (MD or RN), an identification of the product and documentation of administration were entered in the patient's chart, as was done for blood banking protocols. The cells were infused intravenously over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.

**[0209]** One to four days after the last does of fludarabine was administered, the following protocol was followed:

**[0210]** On Day 0 (one to four days after the last dose of fludarabine):

**[0211]** ALVAC Vaccine: Approximately two hours prior to cell infusion, patients will receive 0.5 ml containing a target dose of  $10^7$  CCID<sub>50</sub> (with a range of approximately  $10^{6.4}$  to  $10^{7.9}$ /mL) of the gp100 ALVAC virus S.C. in each extremity (total of  $4 \times 10^7$  CCID<sub>50</sub>/2 mL). This will be repeated on day 14.

**[0212]** Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine). Cell infusions will be given as an inpatient.

**[0213]** Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minute every eight hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)

**[0214]** On Day 1-4 (Day 0 is the day of cell infusion):

**[0215]** Start filgrastim at 10 mcg/kg/day daily on Day 1 or 2 subcutaneously until neutrophil count > $1.0 \times 10^9$ /L x3 days or > $5.0 \times 10^9$ /L (not to exceed 600 µg/day).

**[0216]** Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours for up to 5 days.

**[0217]** On Day 14:

**[0218]** ALVAC Vaccine: Patients will receive 0.5 ml containing a target dose of  $10^7$  CCID<sub>50</sub> (with a range of approximately  $10^{6.4}$  to  $10^{7.9}$ /mL) of the gp100 ALVAC virus S.C. in each extremity (total of  $4 \times 10^7$  CCID<sub>50</sub>/2 mL).

**[0219]** To prevent infection, the following procedures were followed:

**[0220]** All patients received the fixed combination of trimethoprim and sulfamethoxazole [SMX] as double strength (DS) tab (DS tabs=TMP 160 mg/tab, and SMX 800 mg/tab) P.O. daily three times a week on non-consecutive days, beginning on day-7.

[0221] Pentamidine was substituted for TMP/SMX-DS in patients with sulfa allergies. It was administered aerosolized at 300 mg per nebulizer within one week prior to admission and continued monthly thereafter.

[0222] Prophylaxis (either SMX/DS or pentamidine) was continued for 6 months post chemotherapy. If the CD4 count was less than 200 at 6 months post chemotherapy, prophylaxis was continued until the CD4 count is greater than 200.

[0223] Patients with positive HSV serology were given valacyclovir orally at a dose of 500 mg daily the day after chemotherapy ends, or acyclovir, 250 mg/m<sup>2</sup> IV q 12 hrs if the patient was not able to take medication by mouth which was continued until absolute neutrophil count is greater than 1000/mm<sup>3</sup>. Reversible renal insufficiency has been reported with IV but not oral acyclovir. Neurologic toxicity including delirium, tremors, coma, acute psychiatric disturbances, and abnormal EEGs have been reported with higher doses of acyclovir. If this occurred, a dosage adjustment was made or the drug was discontinued. Acyclovir was not used concomitantly with other nucleoside analogs which interfere with DNA synthesis, e.g. ganciclovir. In renal disease, the dose was adjusted as per product labeling.

[0224] Patients started Fluconazole 400 mg p.o. the day after chemotherapy concluded and continued until the absolute neutrophil count was greater than 1000/mm<sup>3</sup>. The drug was given IV at a dose of 400 mg in 0.9% sodium chloride USP daily in patients unable to take it orally.

[0225] Patients started on broad-spectrum antibiotics, either a 3<sup>rd</sup> or 4<sup>th</sup> generation cephalosporin or a quinolone for fever of 38.3° C. once or two temperatures of 38.0° C. or above at least one hour apart, and an ANC < 500/mm<sup>3</sup>. Aminoglycosides were avoided unless clear evidence of sepsis. Infectious disease consultation was obtained for all patients with unexplained fever or any infectious complications.

[0226] Using daily CBC's as a guide, the patient received platelets and packed red blood cells (PRBC's) as needed. Attempts were made to keep Hb > 8.0 gm/dl, and plts > 20,000/mm<sup>3</sup>. All blood products with the exception of the stem cell product were irradiated. Leukocyte filters were utilized for all blood and platelet transfusions to decrease sensitization to transfused WBC's and decrease the risk of CMV infection.

[0227] Aldesleukin (based on total body weight) was administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period every eight hours beginning on the day of cell infusion and continuing for up to 5 days (maximum 15 doses). Doses were skipped depending on patient tolerance. Doses were skipped if patients reach Grade III or IV toxicity due to aldesleukin except for the reversible Grade III toxicities common to aldesleukin such as diarrhea, nausea, vomiting, hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and labo-

ratory changes. Toxicities were managed. If these toxicities were easily reversed within 24 hours by supportive measures then additional doses were given. If greater than 2 doses of aldesleukin were skipped, Aldesleukin administration was stopped. Aldesleukin was administered as an inpatient. Aldesleukin was provided by Novartis Pharmaceuticals Corporation, Florham Park, N.J., if available, and was distributed by the NIH Clinical Pharmacy Department.

[0228] The foregoing demonstrates a method of administering to humans the cells of the invention.

[0229] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0230] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0231] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

---

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 57

<210> SEQ ID NO 1  
 <211> LENGTH: 661  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature

-continued

<223> OTHER INFORMATION: amino acid sequence of human gp100  
(GenBank Accession No. NP\_008859)

<400> SEQUENCE: 1

```

Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
1          5          10          15
Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
20          25          30
Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
35          40          45
Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
50          55          60
Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
65          70          75          80
Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
85          90          95
Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
100         105         110
Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
115         120         125
Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
130         135         140
Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp
145         150         155         160
Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg
165         170         175
Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg
180         185         190
Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr
195         200         205
Ile Thr Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala
210         215         220
Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe
225         230         235         240
Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu
245         250         255
Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg
260         265         270
Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Ala
275         280         285
Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser
290         295         300
Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro
305         310         315         320
Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr
325         330         335
Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln
340         345         350
Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr
355         360         365
Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val
370         375         380

```

-continued

---

```

Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met
385                390                395                400

Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala
                405                410                415

Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro
                420                425                430

Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu
                435                440                445

Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu
                450                455                460

Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr
                465                470                475                480

Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala
                485                490                495

Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu
                500                505                510

Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile
                515                520                525

Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
                530                535                540

Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
                545                550                555                560

Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
                565                570                575

Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
                580                585                590

Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala
                595                600                605

Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
                610                615                620

Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
                625                630                635                640

Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
                645                650                655

Ser Gly Gln Gln Val
                660
    
```

```

<210> SEQ ID NO 2
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: amino acid sequence of variable region of
        alpha chain of Sp(0.01)A TCR
    
```

<400> SEQUENCE: 2

```

Gln Gln Lys Val Gln Gln Ser Pro Glu Ser Leu Ile Val Pro Glu Gly
1                5                10                15

Ala Met Thr Ser Leu Asn Cys Thr Phe Ser Asp Ser Ala Ser Gln Tyr
                20                25                30

Phe Ala Trp Tyr Arg Gln His Ser Gly Lys Ala Pro Lys Ala Leu Met
                35                40                45
    
```



-continued

---

Ser Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr Lys Leu Ile  
100 105 110

Ile Lys Pro Asp  
115

<210> SEQ ID NO 5  
<211> LENGTH: 98  
<212> TYPE: PRT  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: amino acid sequence of variable region of  
beta chain of T2(1)B

<400> SEQUENCE: 5

Asn Ser Gly Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly  
1 5 10 15

Glu Arg Ser Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val  
20 25 30

Ala Trp Tyr Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln  
35 40 45

His Tyr Asp Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe  
50 55 60

Ser Val Gln Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala  
65 70 75 80

Leu Glu Leu Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser  
85 90 95

Gly Ala

<210> SEQ ID NO 6  
<211> LENGTH: 114  
<212> TYPE: PRT  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: amino acid sequence of variable region of  
alpha chain of Sp(0.1)A10

<400> SEQUENCE: 6

Ala Gln Ser Val Thr Gln Pro Asp Ala Arg Val Thr Val Ser Glu Gly  
1 5 10 15

Ala Ser Leu Gln Leu Arg Cys Lys Tyr Ser Tyr Ser Ala Thr Pro Tyr  
20 25 30

Leu Phe Trp Tyr Val Gln Tyr Pro Arg Gln Gly Leu Gln Leu Leu Leu  
35 40 45

Lys Tyr Tyr Ser Gly Asp Pro Val Val Gln Gly Val Asn Ser Phe Glu  
50 55 60

Ala Glu Phe Ser Lys Ser Asn Ser Ser Phe His Leu Gln Lys Ala Ser  
65 70 75 80

Val His Trp Ser Asp Ser Ala Val Tyr Phe Cys Ala Leu Ser His Asp  
85 90 95

Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr Lys Leu Ile Ile Lys  
100 105 110

Pro Asp

-continued

---

<210> SEQ ID NO 7  
 <211> LENGTH: 114  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of variable region  
 of beta chain of Sp(0.1)A10

<400> SEQUENCE: 7

Asn Ser Gly Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly  
 1 5 10 15  
 Glu Arg Ser Ile Leu Lys Cys Ile Pro Ile Ser Gly Tyr Leu Ser Val  
 20 25 30  
 Ala Trp Tyr Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln  
 35 40 45  
 His Tyr Asp Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe  
 50 55 60  
 Ser Val Gln Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala  
 65 70 75 80  
 Leu Glu Leu Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ala  
 85 90 95  
 Gly Val Asn Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr  
 100 105 110  
 Val Leu

<210> SEQ ID NO 8  
 <211> LENGTH: 116  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of the variable region of  
 the alpha chain of T2(1)C

<400> SEQUENCE: 8

Glu Ser His Gly Glu Lys Val Glu Gln His Glu Ser Thr Leu Ser Val  
 1 5 10 15  
 Arg Glu Gly Asp Ser Ala Val Ile Asn Cys Thr Tyr Thr Asp Thr Ala  
 20 25 30  
 Ser Ser Tyr Phe Pro Trp Tyr Lys Gln Glu Ala Gly Lys Ser Leu His  
 35 40 45  
 Phe Val Ile Asp Ile Arg Ser Asn Val Asp Arg Lys Gln Ser Gln Arg  
 50 55 60  
 Leu Ile Val Leu Leu Asp Lys Lys Ala Lys Arg Phe Ser Leu His Ile  
 65 70 75 80  
 Thr Ala Thr Gln Pro Glu Asp Ser Ala Ile Tyr Phe Cys Ala Ala Ser  
 85 90 95  
 Ser Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr Lys Leu Ile  
 100 105 110  
 Ile Lys Pro Asp  
 115

<210> SEQ ID NO 9  
 <211> LENGTH: 114  
 <212> TYPE: PRT

-continued

---

<213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of the variable region of  
 the beta chain of T2(1)C

<400> SEQUENCE: 9

Asn Ser Gly Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly  
 1 5 10 15  
 Lys Arg Ser Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val  
 20 25 30  
 Ala Trp Tyr Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln  
 35 40 45  
 His Tyr Asp Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe  
 50 55 60  
 Ser Val Gln Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala  
 65 70 75 80  
 Leu Glu Leu Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser  
 85 90 95  
 Gly Ala Asn Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr  
 100 105 110  
 Val Leu

<210> SEQ ID NO 10  
 <211> LENGTH: 267  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of alpha chain of  
 Sp(0.01)A TCR

<400> SEQUENCE: 10

Met Lys Ser Leu Ser Val Ser Leu Val Val Leu Trp Leu Gln Leu Asn  
 1 5 10 15  
 Trp Val Asn Ser Gln Gln Lys Val Gln Gln Ser Pro Glu Ser Leu Ile  
 20 25 30  
 Val Pro Glu Gly Ala Met Thr Ser Leu Asn Cys Thr Phe Ser Asp Ser  
 35 40 45  
 Ala Ser Gln Tyr Phe Ala Trp Tyr Arg Gln His Ser Gly Lys Ala Pro  
 50 55 60  
 Lys Ala Leu Met Ser Ile Phe Ser Asn Gly Glu Lys Glu Glu Gly Arg  
 65 70 75 80  
 Phe Thr Ile His Leu Asn Lys Ala Ser Leu His Phe Ser Leu His Ile  
 85 90 95  
 Arg Asp Ser Gln Pro Ser Asp Ser Ala Leu Tyr Leu Cys Ala Ala Asn  
 100 105 110  
 Asn Tyr Ala Gln Gly Leu Thr Phe Gly Leu Gly Thr Arg Val Ser Val  
 115 120 125  
 Phe Pro Tyr Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln Leu Lys Asp  
 130 135 140  
 Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp Phe Asp Ser  
 145 150 155 160  
 Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe Ile Thr Asp  
 165 170 175

-continued

---

Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn Gly Ala  
 180 185 190

Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile Phe Lys  
 195 200 205

Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp Ala Thr  
 210 215 220

Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe Gln Asn  
 225 230 235 240

Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala Gly Phe  
 245 250 255

Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser  
 260 265

<210> SEQ ID NO 11  
 <211> LENGTH: 303  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of beta chain  
 of Sp(0.01)A TCR

<400> SEQUENCE: 11

Met Gly Ser Arg Leu Phe Phe Val Val Leu Ile Leu Leu Cys Ala Lys  
 1 5 10 15

His Met Glu Ala Ala Val Thr Gln Ser Pro Arg Ser Lys Val Ala Val  
 20 25 30

Thr Gly Gly Lys Val Thr Leu Ser Cys His Gln Thr Asn Asn His Asp  
 35 40 45

Tyr Met Tyr Trp Tyr Arg Gln Asp Thr Gly His Gly Leu Arg Leu Ile  
 50 55 60

His Tyr Ser Tyr Val Ala Asp Ser Thr Glu Lys Gly Asp Ile Pro Asp  
 65 70 75 80

Gly Tyr Lys Ala Ser Arg Pro Ser Gln Glu Asn Phe Ser Leu Ile Leu  
 85 90 95

Glu Leu Ala Ser Leu Ser Gln Thr Ala Val Tyr Phe Cys Ala Ser Ser  
 100 105 110

Pro Gly Gly Gly Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr  
 115 120 125

Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe  
 130 135 140

Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Arg Lys Ala Thr Leu Val  
 145 150 155 160

Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp  
 165 170 175

Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala  
 180 185 190

Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg Leu Arg Val  
 195 200 205

Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val  
 210 215 220

Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro  
 225 230 235 240

-continued

---

Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp  
245 250 255

Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr  
260 265 270

Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu  
275 280 285

Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser  
290 295 300

<210> SEQ ID NO 12

<211> LENGTH: 271

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: amino acid sequence of alpha chain of T2(1)B

<400> SEQUENCE: 12

Met Met Lys Thr Ser Leu His Thr Val Phe Leu Phe Leu Trp Leu Trp  
1 5 10 15

Met Asp Trp Glu Ser His Gly Glu Lys Val Glu Gln His Glu Ser Thr  
20 25 30

Leu Ser Val Arg Glu Gly Asp Ser Ala Val Ile Asn Cys Thr Tyr Thr  
35 40 45

Asp Thr Ala Ser Ser Tyr Phe Pro Trp Tyr Lys Gln Glu Ala Gly Lys  
50 55 60

Ser Leu His Phe Val Ile Asp Ile Arg Ser Asn Val Asp Arg Lys Gln  
65 70 75 80

Ser Gln Arg Leu Ile Val Leu Leu Asp Lys Lys Ala Lys Arg Phe Ser  
85 90 95

Leu His Ile Thr Ala Thr Gln Pro Glu Asp Ser Ala Ile Tyr Phe Cys  
100 105 110

Ala Ala Ser Ser Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr  
115 120 125

Lys Leu Ile Ile Lys Pro Asp Ile Gln Asn Pro Glu Pro Ala Val Tyr  
130 135 140

Gln Leu Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr  
145 150 155 160

Asp Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr  
165 170 175

Phe Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys  
180 185 190

Ser Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln  
195 200 205

Asp Ile Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro  
210 215 220

Cys Asp Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu  
225 230 235 240

Asn Phe Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Lys  
245 250 255

Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser  
260 265 270

-continued

---

<210> SEQ ID NO 13  
 <211> LENGTH: 316  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of beta chain of T2(1)B

<400> SEQUENCE: 13

Met Ser Asn Thr Ala Phe Pro Asp Pro Ala Trp Asn Thr Thr Leu Leu  
 1 5 10 15

Ser Trp Val Ala Leu Phe Leu Leu Gly Thr Ser Ser Ala Asn Ser Gly  
 20 25 30

Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly Glu Arg Ser  
 35 40 45

Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val Ala Trp Tyr  
 50 55 60

Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln His Tyr Asp  
 65 70 75 80

Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe Ser Val Gln  
 85 90 95

Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala Leu Glu Leu  
 100 105 110

Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser Gly Ala Asn  
 115 120 125

Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu  
 130 135 140

Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe Glu Pro Ser  
 145 150 155 160

Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala Thr Leu Val Cys Leu Ala  
 165 170 175

Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly  
 180 185 190

Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala Tyr Lys Glu  
 195 200 205

Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr  
 210 215 220

Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His  
 225 230 235 240

Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val  
 245 250 255

Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Ile  
 260 265 270

Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr  
 275 280 285

Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Thr  
 290 295 300

Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser  
 305 310 315

<210> SEQ ID NO 14  
 <211> LENGTH: 269  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:

-continued

<221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of the alpha chain of TCR  
 of clone Sp(0.1)A10

<400> SEQUENCE: 14

```

Met Leu Leu Ala Leu Leu Pro Val Leu Gly Ile His Phe Val Leu Arg
1           5           10           15
Asp Ala Gln Ala Gln Ser Val Thr Gln Pro Asp Ala Arg Val Thr Val
           20           25           30
Ser Glu Gly Ala Ser Leu Gln Leu Arg Cys Lys Tyr Ser Tyr Ser Ala
           35           40           45
Thr Pro Tyr Leu Phe Trp Tyr Val Gln Tyr Pro Arg Gln Gly Leu Gln
           50           55           60
Leu Leu Leu Lys Tyr Tyr Ser Gly Asp Pro Val Val Gln Gly Val Asn
65           70           75           80
Ser Phe Glu Ala Glu Phe Ser Lys Ser Asn Ser Ser Phe His Leu Gln
           85           90           95
Lys Ala Ser Val His Trp Ser Asp Ser Ala Val Tyr Phe Cys Ala Leu
           100          105          110
Ser His Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr Lys Leu
           115          120          125
Ile Ile Lys Pro Asp Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln Leu
           130          135          140
Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp Phe
145          150          155          160
Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe Ile
           165          170          175
Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn
           180          185          190
Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile
           195          200          205
Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp
           210          215          220
Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe
225          230          235          240
Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala
           245          250          255
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
           260          265

```

<210> SEQ ID NO 15  
 <211> LENGTH: 316  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: amino acid sequence of beta chain of TCR of  
 clone Sp(0.1)A10

<400> SEQUENCE: 15

```

Met Ser Asn Thr Ala Phe Pro Asp Pro Ala Trp Asn Thr Thr Leu Leu
1           5           10           15
Ser Trp Val Ala Leu Phe Leu Leu Gly Thr Ser Ser Ala Asn Ser Gly
           20           25           30

```

-continued

---

Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly Glu Arg Ser  
 35 40 45  
 Ile Leu Lys Cys Ile Pro Ile Ser Gly Tyr Leu Ser Val Ala Trp Tyr  
 50 55 60  
 Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln His Tyr Asp  
 65 70 75 80  
 Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe Ser Val Gln  
 85 90 95  
 Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala Leu Glu Leu  
 100 105 110  
 Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ala Gly Val Asn  
 115 120 125  
 Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu  
 130 135 140  
 Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe Glu Pro Ser  
 145 150 155 160  
 Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala Thr Leu Val Cys Leu Ala  
 165 170 175  
 Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly  
 180 185 190  
 Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala Tyr Lys Glu  
 195 200 205  
 Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr  
 210 215 220  
 Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His  
 225 230 235 240  
 Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val  
 245 250 255  
 Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Ile  
 260 265 270  
 Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr  
 275 280 285  
 Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Thr  
 290 295 300  
 Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser  
 305 310 315

&lt;210&gt; SEQ ID NO 16

&lt;211&gt; LENGTH: 271

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Mus musculus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

<223> OTHER INFORMATION: amino acid sequence of alpha chain of TCR  
from clone T2(1)C

&lt;400&gt; SEQUENCE: 16

Met Met Lys Thr Ser Leu His Thr Val Phe Leu Phe Leu Trp Leu Trp  
 1 5 10 15  
 Met Asp Trp Glu Ser His Gly Glu Lys Val Glu Gln His Glu Ser Thr  
 20 25 30  
 Leu Ser Val Arg Glu Gly Asp Ser Ala Val Ile Asn Cys Thr Tyr Thr  
 35 40 45

-continued

---

```

Asp Thr Ala Ser Ser Tyr Phe Pro Trp Tyr Lys Gln Glu Ala Gly Lys
 50                               55                               60

Ser Leu His Phe Val Ile Asp Ile Arg Ser Asn Val Asp Arg Lys Gln
 65                               70                               75                               80

Ser Gln Arg Leu Ile Val Leu Leu Asp Lys Lys Ala Lys Arg Phe Ser
 85                               90                               95

Leu His Ile Thr Ala Thr Gln Pro Glu Asp Ser Ala Ile Tyr Phe Cys
 100                               105                               110

Ala Ala Ser Ser Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ser Gly Thr
 115                               120                               125

Lys Leu Ile Ile Lys Pro Asp Ile Gln Asn Pro Glu Pro Ala Val Tyr
 130                               135                               140

Gln Leu Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr
 145                               150                               155                               160

Asp Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr
 165                               170                               175

Phe Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys
 180                               185                               190

Ser Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln
 195                               200                               205

Asp Ile Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro
 210                               215                               220

Cys Asp Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu
 225                               230                               235                               240

Asn Phe Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys
 245                               250                               255

Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
 260                               265                               270

```

&lt;210&gt; SEQ ID NO 17

&lt;211&gt; LENGTH: 316

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Mus musculus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

<223> OTHER INFORMATION: amino acid sequence of the beta chain of TCR  
from clone T2(1)C

&lt;400&gt; SEQUENCE: 17

```

Met Ser Asn Thr Ala Phe Pro Asp Pro Ala Trp Asn Thr Thr Leu Leu
 1                               5                               10                               15

Ser Trp Val Ala Leu Phe Leu Leu Gly Thr Ser Ser Ala Asn Ser Gly
 20                               25                               30

Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly Lys Arg Ser
 35                               40                               45

Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val Ala Trp Tyr
 50                               55                               60

Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln His Tyr Asp
 65                               70                               75                               80

Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe Ser Val Gln
 85                               90                               95

Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala Leu Glu Leu
 100                               105                               110

```

-continued

---

Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser Gly Ala Asn  
 115 120 125

Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu  
 130 135 140

Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe Glu Pro Ser  
 145 150 155 160

Lys Ala Glu Ile Ala Asn Lys Arg Lys Ala Thr Leu Val Cys Leu Ala  
 165 170 175

Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly  
 180 185 190

Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala Tyr Lys Glu  
 195 200 205

Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Cys Leu Arg Val Ser Ala Thr  
 210 215 220

Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His  
 225 230 235 240

Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val  
 245 250 255

Thr Gln Asp Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Ile  
 260 265 270

Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr  
 275 280 285

Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Thr  
 290 295 300

Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser  
 305 310 315

<210> SEQ ID NO 18  
 <211> LENGTH: 333  
 <212> TYPE: DNA  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: nucleotide sequence of variable region of  
 alpha chain of Sp(0.01)A TCR

<400> SEQUENCE: 18

cagcagaagg tgcagcagag cccagaatcc ctcatgtgcc cagagggagc catgacctct 60

ctcaactgca ctttcagcga cagtgtctct cagtattttg catggtacag acagcattct 120

gggaaagccc ccaaggcact gatgtccatc ttctccaatg gtgaaaaaga agaaggcaga 180

ttcacaattc acctcaataa agccagctcg catttctcgc tacacatcag agactcccag 240

cccagtgact ctgctctcta cctctgtgca gccataaact atgccagggg attaaccttc 300

ggtcttggca ccagagtatc tegtgttccc tac 333

<210> SEQ ID NO 19  
 <211> LENGTH: 336  
 <212> TYPE: DNA  
 <213> ORGANISM: Mus musculus  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: nucleotide sequence of variable region of  
 beta chain of Sp(0.01)A TCR

---

-continued

---

<400> SEQUENCE: 19

gaggctgcag tcacccaaag tccaagaagc aaggtggcag taacaggagg aaaggtgaca 60  
ttgagctgtc accagactaa taaccatgac tatatgtact ggtatcggca ggacacgggg 120  
catgggctga ggctgatcca ttactcatat gtcgctgaca gcacggagaa aggagatatac 180  
cctgatgggt acaaggcctc cagaccaagc caagagaatt tctctctcat tctggagttg 240  
gcttcccttt ctcagacagc tgtatatttc tgtgccagca gccctggggg ggggggggaa 300  
cagtacttcg gtcccggcac caggctcacy gtttta 336

<210> SEQ ID NO 20

<211> LENGTH: 349

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence of variable region of  
alpha chain of T2(1)B

<400> SEQUENCE: 20

ggagagccat ggagagaagg tcgagcaaca tgagtctaca ctgagtgttc gagagggaga 60  
cagcgctgtc atcaactgca cttacacaga tactgcttca tcatacttcc cttggtacaa 120  
gcaagaagct gaaagagctc tccactttgt gatagacatt cgttcaaatg tggacagaaa 180  
acagagccaa agacttatag ttttgttggg taagaaagcc aaacgattct cctgcacat 240  
cacagccaca cagcctgaag attcagccat ctacttctgt gcagcaagct cggatagcaa 300  
ctatcagttg atctggggct ctgggaccaa gctaattata aagccagac 349

<210> SEQ ID NO 21

<211> LENGTH: 342

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence of variable region of  
beta chain of T2(1)B

<400> SEQUENCE: 21

aattctgggg ttgtccagtc tccaagatac ataatcaaag gaaagggaga aaggtccatt 60  
ctaaaatgta ttcccatctc tggacatctc tctgtggcct ggtatcaaca gactcagggg 120  
caggaactaa agttcttcat tcagcattat gataaaatgg agagagataa aggaaacctg 180  
cccagcagat tctcagtcca acagtttgat gactatcact ctgagatgaa catgagtgcc 240  
ttggagctag aggactctgc cgtgtacttc tgtgccagct ctctttctgg ggcgaactat 300  
gctgagcagt tctteggacc agggacacga ctcaccgtcc ta 342

<210> SEQ ID NO 22

<211> LENGTH: 342

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence of variable region  
of alpha chain of Sp(0.1)A10

---

-continued

---

<400> SEQUENCE: 22

```
gctcagtcag tgacacagcc cgatgctcgc gtcactgtct ctgaaggagc ctctctgcag    60
ctgagatgca agtattccta ctctgcgaca ccttatctgt tctggatgtt ccagtaccgc    120
cggcaggggc tgcagctgct cctcaagtac tattcaggag acccagtggg tcaaggagtg    180
aacagcttcg aggctgagtt cagcaagagt aactcttctt tccacctgca gaaagcctct    240
gtgcactgga ggcactcggc tgtgtacttc tgtgctctga gccacgatag caactatcag    300
ttgatctggg gctctgggac caagctaatt ataaagccag ac                          342
```

<210> SEQ ID NO 23

<211> LENGTH: 342

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence of variable region of  
beta chain of Sp(0.1)A10

<400> SEQUENCE: 23

```
aattctgggg ttgtccagtc tccaagatag ataatcaaag gaaagggaga aaggtccatt    60
ctaaaatgta ttccatcttc tggatatctc tctgtggcct ggtatcaaca gactcagggg    120
caggaactaa agttcttctt tcagcattat gataaaatgg agagagataa aggaaacctg    180
cccagcagat tctcagtcga acagtttgat gactatcact ctgagatgaa catgagtgcc    240
ttggagctag aggactctgc cgtgtacttc tgtgccagct ctctcggggg ggttaactat    300
gctgagcagt tcttcggacc agggacacga ctcaccgtcc ta                          342
```

<210> SEQ ID NO 24

<211> LENGTH: 698

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence of variable region of  
alpha chain of T2(1)C

<400> SEQUENCE: 24

```
ggagagccat ggagagaagg tcgagcaaca tgagtctaca ctgagtgttc gagagggaga    60
cagcgtgtgc atcaactgca cttacacaga tactgcttca tcatacttcc cttggtacaa    120
gcaagaagct gaaaagagtc tccactttgt gatagacatt cgttcaaatg tggacagaaa    180
acagagccaa agacttatag ttttgttggg taagaaagcc aaacgattct cctgcacat    240
cacagccaca cagcctgaag attcagccat ctacttctgt gcagcaagct cggatagcaa    300
ctatcagttg atctggggct ctgggaccaa gctaattata aagccagacg gagagccatg    360
gagagaaggt cgagcaacat gagtctacac tgagtgttcg agagggagac agcgtgtgca    420
tcaactgcac ttacacagat actgcttcat catacttccc ttggtacaag caagaagctg    480
gaaagagtct ccactttgtg atagacattc gttcaaatgt ggacagaaaa cagagccaaa    540
gacttatagt tttgttggat aagaaagcca aacgattctc cctgcacatc acagccacac    600
agcctgaaga ttcagccatc tacttctgtg cagcaagctc gtagtagaac tatcagttga    660
tctggggctc tgggaccaag ctaattataa agccagac                          698
```

---

-continued

---

<210> SEQ ID NO 25  
<211> LENGTH: 342  
<212> TYPE: DNA  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: nucleotide sequence of variable region of  
beta chain of T2(1)C  
  
<400> SEQUENCE: 25  
  
aattctgggg ttgtccagtc tccaagatac ataatcaaag gaaagggaaa aaggtccatt 60  
ctaaaatgta ttcccatctc tggacatctc tctgtggcct ggtatcaaca gactcagggg 120  
caggaactaa agttcttcat tcagcattat gataaaatgg agagagataa aggaaacctg 180  
cccagcagat tctcagtcga acagtttgat gactatcact ctgagatgaa catgagtgcc 240  
ttggagctag aggactctgc cgtgtacttc tgtgccagct ctctttctgg ggcgaactat 300  
gctgagcagt tcttcggacc agggacacga ctccacgtcc ta 342

<210> SEQ ID NO 26  
<211> LENGTH: 804  
<212> TYPE: DNA  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: cDNA of alpha chain of Sp(0.01)A TCR  
  
<400> SEQUENCE: 26  
  
atgaaatcct tgagtgtttc cctagtggtc ctgtggctcc agttaaactg ggtgaacagc 60  
cagcagaagg tgcagcagag ccagaaatcc ctccattgtcc cagagggagc catgacctct 120  
ctcaactgca ctttcagcga cagtgtctct cagtattttg catggtacag acagcattct 180  
gggaaagccc ccaaggcact gatgtccatc ttctccaatg gtgaaaaaga agaaggcaga 240  
ttcacaattc acctcaataa agccagtctg catttctcgc tacacatcag agactcccag 300  
cccagtgact ctgctctcta cctctgtgca gccataaact atgccagggg attaaccttc 360  
ggctcttgga ccagagtatc tgtgtttccc tacatccaga acccagaacc tgctgtgtac 420  
cagttaaaag atccctggtc tcaggacagc accctctgcc tgttcaccga ctttgactcc 480  
caaatcaatg tgccgaaaac catggaatct ggaacgttca tcaactgaaa aactgtgctg 540  
gacatgaaag ctatggattc caagagcaat ggggccattg cctggagcaa ccagacaagc 600  
ttcacctgcc aagatatctt caaagagacc aacgccacct accccagttc agacgttccc 660  
tgtgatgcca cgttgactga gaaaagcttt gaaacagata tgaacctaaa ctttcaaac 720  
ctgtcagtta tgggactccg aatcctcctg ctgaaagtag ccggatttaa cctgctcatg 780  
acgctgaggc tgtggtccag ttga 804

<210> SEQ ID NO 27  
<211> LENGTH: 912  
<212> TYPE: DNA  
<213> ORGANISM: Mus musculus  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: cDNA of beta chain of Sp(0.01)A TCR  
  
<400> SEQUENCE: 27  
  
atgggctcca gactcttctt tgtggttttg attctcctgt gtgcaaaaca catggaggct 60  
gcagtcaccc aaagtccaag aagcaagggt gcagtaacag gaggaaaggt gacattgagc 120

-continued

---

```

tgtcaccaga ctaataacca tgactatatg tactggtatc ggcaggacac ggggcatggg 180
ctgaggctga tccattactc atatgtcgcg gacagcacgg agaaaggaga tatccctgat 240
gggtacaagg cctccagacc aagccaagag aatttctctc tcattctgga gttggcttcc 300
ctttctcaga cagctgtata tttctgtgcc agcagccctg gggggggggg ggaacagtac 360
ttcgggtccc gcaccaggct cacggtttta gaggatctga gaaatgtgac tccaccaag 420
gtctccttgt ttgagccatc aaaagcagag attgcaaaca aacgaaaggc taccctcgtg 480
tgcttgcca ggggcttctt ccctgaccac gtggagctga gctggggggg gaatggcaag 540
gaggtccaca gtggggtcag cacggacctc caggcctaca aggagagcaa ttatagctac 600
tgcttgagca gcgcctgag ggtctctgct accttctggc acaatcctcg aaaccacttc 660
cgctgccaag tgcagttcca tgggctttca gaggaggaca agtggccaga gggctcacc 720
aaacctgtca cacagaacat cagtgcagag gctgggggcc gagcagactg tgggattacc 780
tcagcatcct atcaacaagg ggtcttctct gccaccatcc tctatgagat cctgctaggg 840
aaagccacc cgtatgctgt gcttgtcagt aactgggtgg tgatggctat ggtcaaaaga 900
aagaattcat ga 912

```

&lt;210&gt; SEQ ID NO 28

&lt;211&gt; LENGTH: 816

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus musculus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;223&gt; OTHER INFORMATION: nucleotide sequence encoding the alpha chain of the TCR from clone T2(1) B

&lt;400&gt; SEQUENCE: 28

```

atgatgaaga catcccttca cactgtattc ctattcttgt ggctatggat ggactgggag 60
agccatggag agaaggctga gcaacatgag tctacactga gtgttcgaga gggagacagc 120
gctgtcatca actgcactta cacagatact gcttcatcat acttcccttg gtacaagcaa 180
gaagctggaa agagtctcca ctttgtgata gacattcgtt caaatgtgga cagaaaacag 240
agccaaagac ttatagtttt gttggataag aaagccaaac gattctccct gcacatcaca 300
gccacacagc ctgaagatcc agccatctac ttctgtgcag caagctcgga tagcaactat 360
cagttgatct ggggctctgg gaccaagcta attataaagc cagacatcca gaaccagaa 420
cctgctgtgt accagttaa agatcctcgg tctcaggaca gcaccctctg cctgttcacc 480
gactttgact cccaaatcaa tgtgccgaaa accatggaat ctggaacggt catcactgac 540
aaaactgtgc tggacatgaa agctatggat tccaagagca atggggccat tgctgggagc 600
aaccagacaa gcttaccctg ccaagatatc ttcaaagaga ccaacgccac ctaccccagt 660
tcagacgttc cctgtgatgc cacgttgact gagaaaagct ttgaaacaga tatgaaccta 720
aactttcaaa acctgtcagt tatgggactc cgaatcctcc tgctgaaagt agccggattt 780
aacctgctca tgacgctgag gctgtgggtcc agttga 816

```

&lt;210&gt; SEQ ID NO 29

&lt;211&gt; LENGTH: 951

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus musculus

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

-continued

---

<223> OTHER INFORMATION: nucleotide sequence encoding the beta chain  
of the TCR from cloneT2(1) B

<400> SEQUENCE: 29

```

atgtctaaca ctgccttccc tgaccccgcg tggaacacca cctgctatc ttgggttgct    60
ctctttctcc tgggaacaag ttcagcaaat tctgggggtg tccagtctcc aagatacata    120
atcaaaggaa agggagaaaag gtccattcta aaatgtatc ccatctctgg acatctctct    180
gtggcctggt atcaacagac tcaggggcag gaactaaagt tcttcattca gcattatgat    240
aaaatggaga gagataaagg aaacctgccc agcagattct cagtccaaca gtttgatgac    300
tatactctg agatgaacat gagtgcctg gagctagagg actctgccgt gtacttctgt    360
gccagctctc tttctggggc gaactatgct gagcagttct tcggaccagg gacacgactc    420
accgtcctag aggatctgag aaatgtgact ccaccaagg tctccttggt tgagccatca    480
aaagcagaga ttgcaaaaa acaaaaggct acctcgtgt gcttggccag gggcttcttc    540
cctgaccacg tggagctgag ctggtgggtg aatggcaagg aggtccacag tggggtcagc    600
acggaccctc aggcctacaa ggagagcaat tatagctact gcctgagcag ccgctgagg    660
gtctctgcta ccttctggca caactctega aaccacttcc gotgccaagt gcagttccat    720
gggctttcag aggaggacaa gtggccagag ggctcaccca aacctgtcac acagaacatc    780
agtgcagagg cctggggccg agcagactgt gggattacct cagcatccta tcaacaaggg    840
gtcttctctg ccaccatct ctatgagatc ctgctagggg aagccacct gtatgctgtg    900
cttgtcagta cactggtggt gatggctatg gtcaaaagaa agaattcatg a          951

```

<210> SEQ ID NO 30

<211> LENGTH: 810

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<220> FEATURE:

<221> NAME/KEY: misc\_feature

<223> OTHER INFORMATION: nucleotide sequence encoding the alpha chain  
of the TCR from clone Sp(0.1)A10

<400> SEQUENCE: 30

```

atgctcctgg cgctcctccc agtgctgggg atacactttg tctgagaga tgccaagct    60
cagtcagtga cacagcccca tgctcgcgct actgtctctg aaggagctc tctgcagctg    120
agatgcaagt attcctactc tgcgacacct tatctgttct ggtatgtcca gtaccgcggg    180
caggggctgc agctgctcct caagtactat tcaggagacc cagtggttca aggagtgaac    240
agcttcgagg ctgagttcag caagagtaac tcttccttcc acctgcagaa agcctctgtg    300
cactggagcg actcggctgt gtacttctgt gctctgagcc acgatagcaa ctatcagttg    360
atctggggct ctgggaccaa gctaattata aagccagaca tcagaaacc agaacctgct    420
gtgtaccagt taaaagatcc tcggtctcag gacagcacc tctgctggt caccgacttt    480
gactcccaaa tcaatgtgcc gaaaacctg gaatctggaa cgttcatcac tgacaaaact    540
gtgctggaca tgaagctat ggattccaag agcaatgggg ccattgcctg gagcaaccag    600
acaagcttca cctgccaaag tatcttcaaa gagaccaacg ccacctacc cagttcagac    660
gtccctgtg atgccacgtt gactgagaaa agctttgaaa cagatatgaa cctaaacttt    720
caaaacctgt cagttatggg actccgaatc ctctgctga aagtagccgg atttaacctg    780
ctcatgacgc tgaggctgtg gtccagttga          810

```

-continued

---

```

<210> SEQ ID NO 31
<211> LENGTH: 951
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: nucleotide sequence encoding the beta chain
of the TCR from cloneSp(0.1)A10

```

```

<400> SEQUENCE: 31
atgtctaaca ctgccttccc tgaccccgcc tggaacacca cctgctatc ttgggttget      60
ctctttctcc tgggaacaag ttcagcaaat tctggggttg tccagtctcc aagatacata      120
atcaaaggaa agggagaaaag gtccattcta aaatgtattc ccatactctgg atatctctct      180
gtggcctggt atcaacagac tcaggggcag gaactaaagt tcttcattca gcattatgat      240
aaaatggaga gagataaagg aaacctgccc agcagattct cagtccaaca gtttgatgac      300
tatactctg agatgaacat gagtgccttg gagctagagg actctgcoct gtacttctgt      360
gccagctctc tcgcgggggg taactatgct gagcagttct tcggaccagg gacacgactc      420
accgtcctag aggatctgag aaatgtgact ccaccaagg tctccttgtt tgagccatca      480
aaagcagaga ttgcaaaaca acaaaaggct acctcgtgt gcttggccag gggcttcttc      540
cctgaccacg tggagctgag ctggtgggtg aatggcaagg aggtccacag tggggtcagc      600
acggaccctc aggcctacaa ggagagcaat tatagctact gcctgagcag ccgctgagg      660
gtctctgcta ctttctggca caatcctoga aaccacttcc gctgccaagt gcagttccat      720
gggctttcag aggaggacaa gtggccagag ggctcacca aacctgtcac acagaacatc      780
agtgcagagg cctggggccg agcagactgt gggattacct cagcatccta tcaacaaggg      840
gtcttctctg ccaccatcct ctatgagatc ctgctagggg aagccacct gtatgctgtg      900
cttgctagta cactggtggt gatggctatg gtcaaaagaa agaattcatg a              951

```

```

<210> SEQ ID NO 32
<211> LENGTH: 816
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: nucleotide sequence encoding the alpha chain
of the TCR from clone T2(1) C

```

```

<400> SEQUENCE: 32
atgatgaaga catcccttca cactgtattc ctattcttgt ggctatggat ggactgggag      60
agccatggag agaaggtcga gcaacatgag tctactctga gtgttcgaga gggagacagc      120
gctgtcatca actgcactta cacagatact gtttcatcat acttcccttg gtacaagcaa      180
gaagctggaa agagtctcca ctttgtgata gacattcgtt caaatgtgga cagaaaacag      240
agccaaagac ttatagtttt gttggataag aaagccaaac gattctcctt gcacatcaca      300
gccacacagc ctgaagattc agccatctac ttctgtgcag caagctcgga tagcaactat      360
cagttgatct ggggctctgg gaccaagcta attataaagc cagacatcca gaaccagaa      420
cctgctgtgt accagtaaaa agatcctcgg tctcaggaca gcacctctg cctgttcacc      480
gactttgact cccaaatcaa tgtgccgaaa accatggaat ctggaacgtt catcactgac      540
aaaactgtgc tggacatgaa agctatggat tccaagagca atggggccat tgectggagc      600

```

-continued

---

```

aaccagacaa gcttcacctg ccaagatata ttcaaagaga ccaacgccac ctaccccagt 660
tcagacgttc cctgtgatgc cacgttgact gagaaaagct ttgaacaga tatgaaccta 720
aactttcaaa acctgtcagt tatgggactc cgaatcctcc tgetgaaagt agccggattt 780
aacctgctca tgacgtgag gctgtggtcc agttga 816

```

```

<210> SEQ ID NO 33
<211> LENGTH: 951
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: nucleotide sequence encoding the beta chain
of TCR from cloneT2(1)C

```

```

<400> SEQUENCE: 33

```

```

atgtctaaca ctgccttccc tgaccccgcc tggaaacacca cctgctatac ttgggttgct 60
ctctttctcc tgggaacaag ttcagcaaat tctgggggtg tccagtctcc aagatacata 120
atcaaaggaa agggaaaaag gtccattcta aatgtattc ccatctctgg acatctctct 180
gtggcctggt atcaacagac tcaggggcag gaactaaagt tcttcattca gcattatgat 240
aaaatggaga gagataaagg aaacctgccc agcagattct cagtccaaca gtttgatgac 300
tatcaactctg agatgaacat gagtgccttg gagctagagg actctgccgt gtacttctgt 360
gccagctctc tttctggggc gaactatgct gagcagttct tggaccagg gacacgactc 420
accgtctctag aggatctgag aatgtgact ccaccaagg tctccttggt tgagccatca 480
aaagcagaga ttgcaacaa acgaaaggct acctcgtgt gcttgccag gggcttcttc 540
cctgaccacg tggagctgag ctggtgggtg aatggcaagg aggtccacag tggggtcagc 600
acggaccctc aggcctaaa ggagagcaat tatagctact gcctgagcag ctgcctgagg 660
gtctctgcta cctctggca caatcctcga aaccacttcc gctgccaagt gcagttccat 720
gggctttcag agggaggaaa gtggccagag ggctcacca aacctgtcac acaggacatc 780
agtgcagagg cctggggccg agcagactgt gggattacct cagcatccta tcaacaaggg 840
gtcttgtctg ccaccatct ctacgagatc ctgctagga aagccacct gtatgctgtg 900
cttgtcagta cactggtggt gatggctatg gtcaaagaa agaattcatg a 951

```

```

<210> SEQ ID NO 34
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: amino acid sequence of human gp100 epitope

```

```

<400> SEQUENCE: 34

```

```

Lys Thr Trp Gly Gln Tyr Trp Gln Val
1 5

```

```

<210> SEQ ID NO 35
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

```

-continued

---

<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: amino acid sequence of murine gp100 epitope  
  
<400> SEQUENCE: 35  
  
Lys Thr Trp Gly Lys Tyr Trp Gln Val  
1 5

<210> SEQ ID NO 36  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRAC  
  
<400> SEQUENCE: 36  
  
ggctactttc agcaggagga 20

<210> SEQ ID NO 37  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRBC  
  
<400> SEQUENCE: 37  
  
aggcctctgc actgatgttc 20

<210> SEQ ID NO 38  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRACseq  
  
<400> SEQUENCE: 38  
  
actggtacac agcaggttct gg 22

<210> SEQ ID NO 39  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRBCseq  
  
<400> SEQUENCE: 39  
  
aaggagacct tgggtggagt c 21

<210> SEQ ID NO 40  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

---

-continued

---

<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 5'TRA7D3\*01  
  
<400> SEQUENCE: 40  
  
caccatgaaa tccttgagtg tttcc 25  
  
<210> SEQ ID NO 41  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRA  
  
<400> SEQUENCE: 41  
  
tcaactggac cacagcctca gc 22  
  
<210> SEQ ID NO 42  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 5'TRB13-3\*01  
  
<400> SEQUENCE: 42  
  
caccatgggc tccagactct tcttt 25  
  
<210> SEQ ID NO 43  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRBC  
  
<400> SEQUENCE: 43  
  
aggcctctgc actgatgttc 20  
  
<210> SEQ ID NO 44  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 5' TCRBCseqreverse  
  
<400> SEQUENCE: 44  
  
aaggagacct tgggtggagt c 21  
  
<210> SEQ ID NO 45  
<211> LENGTH: 28  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:

-continued

---

<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRB  
  
<400> SEQUENCE: 45  
  
tcatgaattc tttcttttga ccatagcc 28

<210> SEQ ID NO 46  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 5'TRB13-3\*01  
  
<400> SEQUENCE: 46  
  
caccatgggc tccagactct tcttt 25

<210> SEQ ID NO 47  
<211> LENGTH: 28  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' TCRB  
  
<400> SEQUENCE: 47  
  
tcatgaattc tttcttttga ccatagcc 28

<210> SEQ ID NO 48  
<211> LENGTH: 51  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 5' alpha RNA  
  
<400> SEQUENCE: 48  
  
aactaatcag actcactata gggagacacc atgaaatcct tgagtgtttc c 51

<210> SEQ ID NO 49  
<211> LENGTH: 86  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<223> OTHER INFORMATION: primer 3' alpha RNA  
  
<400> SEQUENCE: 49  
  
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60  
  
tttttcaact ggaccacagc ctcagc 86

<210> SEQ ID NO 50  
<211> LENGTH: 51  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

-continued

---

```

<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: primer 5' beta RNA

<400> SEQUENCE: 50
aactaatcag actcactata gggagacacc atgggctcca gactttttt t      51

<210> SEQ ID NO 51
<211> LENGTH: 93
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: primer 3' beta RNA

<400> SEQUENCE: 51
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt      60
ttttttcatg aattttttct tttgaccata gcc                                93

<210> SEQ ID NO 52
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: amino acid sequence of variable region of
T2(1)B/C with variation X at position 17 is any amino acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 52
Asn Ser Gly Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly
1          5          10          15
Xaa Arg Ser Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val
          20          25          30
Ala Trp Tyr Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln
          35          40          45
His Tyr Asp Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe
          50          55          60
Ser Val Gln Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala
65          70          75          80
Leu Glu Leu Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser
          85          90          95
Gly Ala

<210> SEQ ID NO 53
<211> LENGTH: 316
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: amino acid sequence of T2(1)B/C with variations
X at position 46, 168, 218, and/or 259 is/are any amino acid.
<220> FEATURE:
<221> NAME/KEY: misc_feature

```

-continued

---

<222> LOCATION: (46)..(46)  
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (168)..(168)  
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (218)..(218)  
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (259)..(259)  
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 53

```

Met Ser Asn Thr Ala Phe Pro Asp Pro Ala Trp Asn Thr Thr Leu Leu
1           5           10           15

Ser Trp Val Ala Leu Phe Leu Leu Gly Thr Ser Ser Ala Asn Ser Gly
          20           25           30

Val Val Gln Ser Pro Arg Tyr Ile Ile Lys Gly Lys Gly Xaa Arg Ser
          35           40           45

Ile Leu Lys Cys Ile Pro Ile Ser Gly His Leu Ser Val Ala Trp Tyr
          50           55           60

Gln Gln Thr Gln Gly Gln Glu Leu Lys Phe Phe Ile Gln His Tyr Asp
65           70           75           80

Lys Met Glu Arg Asp Lys Gly Asn Leu Pro Ser Arg Phe Ser Val Gln
          85           90           95

Gln Phe Asp Asp Tyr His Ser Glu Met Asn Met Ser Ala Leu Glu Leu
          100          105          110

Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ser Gly Ala Asn
          115          120          125

Tyr Ala Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu
          130          135          140

Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe Glu Pro Ser
145          150          155          160

Lys Ala Glu Ile Ala Asn Lys Xaa Lys Ala Thr Leu Val Cys Leu Ala
          165          170          175

Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
          180          185          190

Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala Tyr Lys Glu
          195          200          205

Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Xaa Leu Arg Val Ser Ala Thr
210          215          220

Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His
225          230          235          240

Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val
          245          250          255

Thr Gln Xaa Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Ile
          260          265          270

Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr
          275          280          285

Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Thr
          290          295          300

Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser
305          310          315

```

-continued

---

```

<210> SEQ ID NO 54
<211> LENGTH: 303
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: amino acid sequence beta chain of Sp(0.01)A
with variation inconstant region
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (205)..(205)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (238)..(238)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 54

Met Gly Ser Arg Leu Phe Phe Val Val Leu Ile Leu Leu Cys Ala Lys
 1             5             10             15

His Met Glu Ala Ala Val Thr Gln Ser Pro Arg Ser Lys Val Ala Val
             20             25             30

Thr Gly Gly Lys Val Thr Leu Ser Cys His Gln Thr Asn Asn His Asp
 35             40             45

Tyr Met Tyr Trp Tyr Arg Gln Asp Thr Gly His Gly Leu Arg Leu Ile
 50             55             60

His Tyr Ser Tyr Val Ala Asp Ser Thr Glu Lys Gly Asp Ile Pro Asp
 65             70             75             80

Gly Tyr Lys Ala Ser Arg Pro Ser Gln Glu Asn Phe Ser Leu Ile Leu
             85             90             95

Glu Leu Ala Ser Leu Ser Gln Thr Ala Val Tyr Phe Cys Ala Ser Ser
 100            105            110

Pro Gly Gly Gly Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
 115            120            125

Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe
 130            135            140

Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Arg Lys Ala Thr Leu Val
 145            150            155            160

Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp
 165            170            175

Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala
 180            185            190

Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Xaa Leu Arg Val
 195            200            205

Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val
 210            215            220

Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Xaa Ser Pro
 225            230            235            240

Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp
 245            250            255

Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr
 260            265            270

```

-continued

Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu  
 275 280  
 Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser  
 290 295 300

<210> SEQ ID NO 55  
 <211> LENGTH: 423  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Human alpha chain constant region

<400> SEQUENCE: 55

atccagaacc ctgaccctgc cgtgtaccag ctgagagact ctaaatccag tgacaagtct 60  
 gtctgcctat tcaccgattt tgattctcaa acaaatgtgt cacaaagtaa ggattctgat 120  
 gtgtatatca cagacaaaac tgtgctagac atgaggtcta tggacttcaa gagcaacagt 180  
 gctgtggcct ggagcaacaa atctgacttt gcatgtgcaa acgccttcaa caacagcatt 240  
 attccagaag acaccttctt cccagccca gaaagtctct gtgatgcaa gctggctcag 300  
 aaaagctttg aaacagatac gaacctaaac tttcaaaacc tgtcagtgat tgggttccga 360  
 atcctctctc tgaaagtggc cgggtttaat ctgctcatga cgctcggct gtggtccagc 420  
 tga 423

<210> SEQ ID NO 56  
 <211> LENGTH: 534  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <223> OTHER INFORMATION: Human beta chain constant region

<400> SEQUENCE: 56

gaggacctga acaaggtggt cccaccagag gtcgctgtgt ttgagccatc agaagcagag 60  
 atctcccaca cccaaaaggc cacactgggtg tgccctggcca caggcttctt cctgaccac 120  
 gtggagctga gctgggtgggt gaatgggaag gaggtgcaca gtggggtcag cacggaccgc 180  
 cagcccctca aggagcagcc gccctcaat gactccagat actgcctgag cagccgcctg 240  
 agggctctcg ccaccttctg gcagaacccc cgcaaccact tccgctgtca agtccagttc 300  
 tacgggtctc cggagaatga cgagtggacc caggataggg ccaaaccgt caccagatc 360  
 gtcagcgcgc aggcctgggg tagagcagac tgtggcttta cctcgggtgc ctaccagcaa 420  
 ggggtctctg ctgccacct cctctatgag atcctgctag ggaaggccac cctgtatgct 480  
 gtgctgtgca ggcctctgt gttgatggcc atggtaaga gaaaggattt ctga 534

<210> SEQ ID NO 57  
 <211> LENGTH: 7929  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic  
 <220> FEATURE:  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (7552)..(7555)  
 <223> OTHER INFORMATION: n is a, c, g, or t

-continued

&lt;400&gt; SEQUENCE: 57

---

```

ccatgtcacc cttgagtgtt tcctagtgg tcctgtggct ccagttaaac tgggtgaaca    60
gccagcagaa ggtgcagcag agcccagaat ccctcattgt cccagagggga gccatgacct    120
ctctcaactg cactttcagc gacagtgctt ctcagtattt tgcattggac agacagcatt    180
ctgggaaaag ccccaggca ctgatgtcca tcttctccaa tggtgaaaaa gaagaaggca    240
gattcacaat tcacctcaat aaagccagtc tgcatttctc gctacacatc agagactccc    300
agcccagtga ctctgctctc tacctctgtg cagccaataa ctatgcccag ggattaacct    360
tcggtcttgg caccagagta tctgtgttcc cctacatcca gaaccagaa cctgctgtgt    420
accagttaaa agatcctcgg tctcaggaca gcaccctctg cctgttcacc gactttgact    480
cccaaatcaa tgtgccgaaa accatggaat ctggaacggt catcactgac aaaactgtgc    540
tggacatgaa agctatggat tccaagagca atggggccat tgcctggagc aaccagacaa    600
gcttcacctg ccaagatata ttcaagaga ccaacgccac ctaccccagt tcagacgctc    660
cctgtgatgc cacgttgact gagaaaagct ttgaaacaga tatgaaccta aactttcaaa    720
acctgtcagt tatgggactc cgaatcctcc tgcctgaaagt agccggattt aacctgctca    780
tgacgctgag gctgtggtcc agttgagcgg ccgctctaga actagtggat ctccacgtgg    840
cggctagtac tccggtattg cggtagccct gtacgcctgt tttatactcc ctcccgtaa    900
cttagacgca caaaaacca ttcaatagaa gggggtacaa accagtacca ccacgaacaa    960
gcacttctgt ttccccggtg atgtcgtata gactgcttgc gtggttgaaa gcgacggatc   1020
cgttatccgc ttatgtactt cgagaagccc agtaccacct cggaaatctc gatgcgcttc   1080
gctcagcact caaccccaga gtgtagctta ggctgatgag tctggacatc cctcaccggt   1140
gacggtggtc caggctgcgt tggcggccta cctatggcta acgccatggg acgctagttg   1200
tgaacaaggt gtgaagagcc tattgagcta cataagaatc ctccggcccc tgaatgcggc   1260
taatcccaac ctccggagcag gtggtcacia accagtgatt ggctgtcgt aacgcgcaag   1320
tccgtggcgg aaccgactac tttgggtgtc cgtgtttcct tttatattat tgtggctgct   1380
tatggtgaca atcacagatt gttatcataa agcgaattgg ataggatcaa gcttatcgat   1440
gggctccaga ctcttctttg tggttttgat tctcctgtgt gcaaaacaca tggaggctgc   1500
agtcacccaa agtccaagaa gcaagggtgg agtaacagga ggaaagggtga cattgagctg   1560
tcaccagact aataaccatg actatatgta ctggtatcgg caggacacgg ggcattgggt   1620
gaggctgac cattaactcat atgtcgtga cagcacggag aaaggagata tccctgatgg   1680
gtacaaggcc tccagaccaa gccaaagaaa tttctctctc attctggagt tggcttcct   1740
ttctcagaca gctgtatatt tctgtgccag cagccctggg gggggggggg aacagtactt   1800
cggctccggc accagctca cggttttaga ggatctgaga aatgtgactc cacccaaggt   1860
ctccttgttt gagcatcaa aagcagagat tgcaaacaaa cgaaaggcta cctcctgtgt   1920
cttgccagg ggcttcttcc ctgaccacgt ggagctgagc tgggtgggtga atggcaagga   1980
ggtccacagt ggggtcagca cggaccctca ggctacaag gagagcaatt atagctactg   2040
cctgagcagc cgctgaggg tctctgctac cttctggcac aatcctcgaa accacttccg   2100
ctgccaagtg cagttccatg ggctttcaga ggaggacaag tggccagagg gctcacccaa   2160
acctgtcaca cagaacatca gtgcagaggg ctggggccga gcagactgtg ggattacctc   2220

```

-continued

---

```

agcatcctat caacaagggg tcttgtctgc caccatcctc tatgagatcc tgetagggaa 2280
agccaccctg tatgctgtgc ttgtcagtac actggtggtg atggctatgg tcaaaagaaa 2340
gaattcatga taagcttcga attctgcagt cgacggtacc gggggcccgg gatccgataa 2400
aataaaagat tttathtagt ctccagaaaa aggggggaat gaaagacccc acctgtaggt 2460
ttggcaagct agcttaagta acgccatttt gcaaggcatg gaaaatacat aactgagaat 2520
agagaagttc agatcaaggt taggaacaga gagacagcag aatatgggcc aaacaggata 2580
tctgtggtaa gcagttcctg ccccggctca gggccaagaa cagatggtcc ccagatgctg 2640
tcccgcctc agcagtttct agagaacct cagatgttcc cagggtgccc caaggacctg 2700
aaaatgacct tgtgccttat ttgaaactaac caatcagttc gcttctcgtc tctgttcgctg 2760
cgcttctgct ccccagctc aataaaagag cccacaaccc ctcaactcggc gcgccagtcc 2820
tccgatagac tgcgtgcgcc gggtaaccgt gtatccaata aacctcttg cagttgcatc 2880
cgacttgtgg tctcgtgtt ccttgggagg gtctcctctg agtgattgac taccctcag 2940
cgggggtctt tcattggtaa cagtttcttg aagttggaga acaacattct gagggtagga 3000
gtcgaatatt aagtaactct gactcaatta gccactgttt tgaatccaca tactccaata 3060
ctcctgaaat ccatcgatgg agttcattat ggacagcgca gaaagagctg gggagaattg 3120
tgaaattggt atccgtcac aattccacac aacatacgag ccggaagcat aaagtgtaaa 3180
gcctgggggt cctaagtagt gagtaactc acattaattg cgttgcgctc actgccgct 3240
ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa tcggccaacg cgcggggaga 3300
ggcggtttgc gtattgggct ctcttccgct tctcctcctc ctgactcgtc gcgctcggtc 3360
gttcggctgc ggcgagcgg atcagctcac tcaaaggcgg taatacgggt atccacagaa 3420
tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt 3480
aaaaaggcgg cgttgtcggc gtttttccat aggctccgcc cccctgacga gcatcacaaa 3540
aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt 3600
ccccctggaa gctccctcgt gcgctctcct gttccgacct tgcctcttac cggataacctg 3660
tccgccttcc tccctcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc 3720
agttcggtgt aggtcgttc ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc 3780
gaccgctgct ccttatccgg taactatcgt cttgagtcca acccggttaag acacgactta 3840
tcgccactgg cagcagccac tggtaacagg attagcagag cgaggatgt aggcgggtgct 3900
acagagttct tgaagtgggt gcctaactac ggctacacta gaaggacagt atttggtatc 3960
tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa 4020
caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa 4080
aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa 4140
aactcacggt aagggathtt ggctatgaga ttatcaaaaa ggatcttcac ctagatcctt 4200
ttaaattaaa aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggctgac 4260
agttaccaat gcttaacag tgaggcaact atctcagcga tctgtctatt tcttcatcc 4320
atagttgctt gactccccgt cgtgtagata actacgatac gggagggtctt acctctggc 4380
cccagtgctg caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata 4440
aacagccag ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc 4500

```

---

-continued

---

cagtctatta attggtgccc ggaagctaga gtaagtagtt cggcagtaa tagtttgccc 4560  
aacgttgttg ccattgctac aggcacgtg gtgtcacgct cgtcgtttgg tatggcttca 4620  
ttcagctccg gttcccaacg atcaaggcga gttacatgat ccccatggtt gtgcaaaaaa 4680  
gcggttagct ccttcggctc tccgatcgtt gtcagaagta agttggccgc agtggtatca 4740  
ctcatgggta tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt 4800  
tctgtgactg gtgagtactc aaccaagtca ttctgagaat agtgatgccc ggcaccgagt 4860  
tgctcttgcc cggcgtcaat accgggataat accgcgccac atagcagaac tttaaaagtg 4920  
ctcatcattg gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctggtgaga 4980  
tccagttcga tgaaccccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc 5040  
agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg 5100  
acacggaaat gttgaatact catactcttc ctttttcaat attattgaag cattttatcag 5160  
ggttattgtc tcattgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg 5220  
gttcgcgca catttccccg aaaagtgcc cctgacgtct aagaaacat tattatcatg 5280  
acattaacct ataaaaatag gcgtatcacg aggcccttcc gtctcgcgccc ttcggtgat 5340  
gacggtgaaa acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg 5400  
gatgccggga gcagacaagc ccgtcagggc gcgtcagcgg gtgttgccgg gtgtcggggc 5460  
tggttaact atgcggcatc agagcagatt gtactgagag tgaccatat gcggtgtgaa 5520  
ataccgcaca gatgcgtaag gagaaaatac cgcacagggc gccattcggc attcaggctg 5580  
cgcaactggt ggggaagggc atcggtgccc gcctcttccc tattacgcca gctggcgaaa 5640  
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 5700  
tgtaaaacga cggccagtgc cacgctctcc cttatgcgac tctgcatca ggaagcagcc 5760  
cagtagtagg ttgagggcgt tgagcaccgc cgcggcaagg aatggtgcat gcaaggagat 5820  
ggcggccaac agtcccccg ccacggggcc tgccaccata cccacggcga aacaagcgt 5880  
catgagcccg aagtggcgag cccgatcttc cccatcgggt atgtcggcga tataggccc 5940  
agcaaccgca cctgtggcgc cggatgatgcc ggccacgatg cgtccggcgt agaggcgatt 6000  
taaagacagg atactagttg tccaggtctc agttttgact caacaatc accagctgaa 6060  
gcctatagag tacgagccat agataaaata aaagatttta tttagtctcc agaaaaaggg 6120  
gggaatgaaa gaccccacct gtaggtttgg caagctagct taagtaacgc cattttgcaa 6180  
ggcatggaaa atacataact gagaatagag aagttcagat caaggtagg aacagagaga 6240  
cagcagaata tgggcaaac aggatctctg tgtaagcag ttctgcccc ggctcagggc 6300  
caagaacaga tggccccag atgcggctcc gccctcagca gttctagag aaccatcaga 6360  
tgtttccagg gtgccccaaag gacctgaaaa tgacctgtg ccttattga actaaccaat 6420  
cagttcgctt ctgcctctg ttcgcgcgct tctgctcccc gagctcaata aaagagccca 6480  
caacccctca ctgcggcgcg cagtctctcg atagactgcg tgcgggggt acccgctatc 6540  
ccaataaagc ctcttgctgt ttgcatccga atcgtggact cgtgatcct tgggagggtc 6600  
tcctcagatt gattgactgc ccacctcggg ggtctttcat ttggaggttc caccgagatt 6660  
tggagacccc tgccatggga ccaccgaccc ccccgccggg aggtaagctg gccagcggtc 6720  
gtttcgtgtc tgtctctgtc tttgtgctgt tttgtgcccg catctaatgt ttgcgectgc 6780

-continued

---

gtctgtacta gttagetaac tagctctgta tctggcggac ccgtggtgga actgacgagt	6840
tcggaacacc cggccgcaac cctgggagac gtcccaggga cttcgggggc cgtttttgtg	6900
gcccgaacctg agtccaaaaa tcccgatcgt tttggactct ttggtgcacc ccccttagag	6960
gagggatattg tggttctggt aggagacgag aacctaaaac agttcccgcc tccgtctgaa	7020
tttttgcttt cggtttggga ccgaagccgc gccgcgcgtc ttgtctgctg cagcatcgtt	7080
ctgtgttctc tctgtctgac tgtgtttctg tttttgtctg agaatatggg cccgggctag	7140
cctgttacca ctcccctaag tttgacctta ggtcactgga aagatgtcga gcggatcgtc	7200
cacaaccagt cggtagatgt caagaagaga cgttgggta ccttctgctc tgcagaatgg	7260
ccaaccttta acgtcggatg gccgcgagac gccacctta accgagacct catcaccag	7320
gttaagatca aggtcttttc acctggcccg catggacacc cagaccaggt cccctacatc	7380
gtgacctggg aagccttggc ttttgacccc cctccctggg tcaagccctt tgtacaccct	7440
aagcctccgc ctctcttctc tccatccgcc ccgtctctcc ccttgaacc tctctgttcg	7500
accccgctc gatcctcctt ttatccagcc ctcaactcct ctctaggcgc cmmncatat	7560
gagatcttat atggggcacc cccgccctt gtaaaacttc ctgacctga catgacaaga	7620
gttactaaca gccctctct ccaagctcac ttacaggctc tctacttagt ccagcacgaa	7680
gtctggagac ctctggcgcc agcctaccaa gaacaactgg accgaccggt ggtacctcac	7740
ccttaccgag tcggcgacac agtgtgggct cgcgcgacacc agactaagaa cctagaacct	7800
cgctggaag gaccttacac agtctctgctg accaccccca ccgccctcaa agtagacggc	7860
atcgcagctt ggatacacgc gccccacgtg aaggctgccc accccggggg tggaccatcc	7920
tctagaccg	7929

---

1. A human cell comprising a murine T Cell Receptor (TCR) having antigenic specificity for gp100 (SEQ ID NO: 1).

2. The human cell of claim 1, wherein the cell is a T cell.

3. The human cell of claim 1, wherein the TCR has antigenic specificity for amino acids 154-162 of human gp100 (SEQ ID NO: 1).

4. The human cell of claim 1, wherein the TCR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 9.

5. The human cell of claim 4, wherein the TCR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 17.

6. The human cell of claim 4, wherein the TCR comprises SEQ ID NO: 2 and SEQ ID NO: 3.

7. An isolated or purified T Cell Receptor (TCR) having antigenic specificity for amino acids 154-162 of a gp100 protein (SEQ ID NO: 1).

8. The TCR of claim 7, wherein the TCR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 9.

9. The TCR of claim 8, wherein the TCR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 17.

10. The TCR of claim 8, wherein the TCR comprises SEQ ID NO: 2 and SEQ ID NO: 3.

11. An isolated or purified polypeptide comprising a functional portion of the TCR of claim 7, wherein the functional portion specifically binds to amino acids 154-162 of the gp100 protein (SEQ ID NO: 1).

12. The isolated or purified polypeptide of claim 11, wherein the portion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 9.

13. The isolated or purified polypeptide of claim 12, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 17.

14. An isolated or purified protein comprising the polypeptide of claim 11.

15. The isolated or purified protein of claim 14, comprising a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 10 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 11.

16. The isolated or purified protein of claim 14, wherein the protein is a fusion protein.

17. The isolated or purified protein of claim 14, wherein the protein is a recombinant antibody.

18. An isolated or purified nucleic acid comprising a nucleotide sequence encoding the TCR of claim 7.

19. The isolated or purified nucleic acid of claim 18, wherein the nucleotide sequence is selected from a group consisting of SEQ ID NOs: 18 to 25.

**20.** The isolated or purified nucleic acid of claim **19**, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOs: 26 to 33.

**21.** A recombinant expression vector comprising the nucleic acid of claim **18**.

**22.** The recombinant expression vector of claim **21**, wherein the vector is a retroviral vector or a lentiviral vector.

**23.** An isolated host cell comprising the recombinant expression vector of claim **21**.

**24.** The isolated host cell of claim **23**, wherein the cell is a peripheral blood lymphocyte (PBL).

**25.** The isolated host cell of claim **24**, wherein the PBL is a CD8<sup>+</sup> T cell or a CD4<sup>+</sup> T cell.

**26.** A population of cells comprising at least one human cell of claim **1**.

**27.** An antibody, or antigen binding portion thereof, which specifically binds to a functional portion of the TCR of claim **7**, wherein the functional portion specifically binds to amino acids 154-162 of gp100 (SEQ ID NO: 1).

**28.** A conjugate comprising the human cell of claim **1** and a therapeutic agent, a detectable moiety, or both a therapeutic agent and a detectable moiety.

**29.** The conjugate of claim **28**, wherein the therapeutic agent is an anti-cancer therapeutic agent.

**30.** (canceled)

**31.** A pharmaceutical composition comprising the human cell of claim **1**, and a pharmaceutically acceptable carrier.

**32.** A method of detecting the presence of cancer in a host, comprising:

(a) contacting a sample from the host comprising cells of the cancer with the human cell of claim **1**, thereby forming a complex, and

(b) detecting the complex,

wherein detection of the complex is indicative of the presence of cancer in the host.

**33.** A method of treating or preventing cancer in a host, comprising administering to the host the pharmaceutical composition of claim **31** in an amount effective to treat or prevent cancer in the host.

**34.** The method of claim **32**, wherein the cancer is colorectal cancer or melanoma.

**35.** The method of claim **34**, wherein the melanoma is a metastatic melanoma.

**36.** The method of claim **32**, wherein the human cell or host cell is a cell that is autologous to the host.

**37.** (canceled)

\* \* \* \* \*

专利名称(译)	Gp100特异性t细胞受体及相关材料和使用方法		
公开(公告)号	<a href="#">US20100015113A1</a>	公开(公告)日	2010-01-21
申请号	US12/522321	申请日	2008-01-11
[标]申请(专利权)人(译)	美国卫生及公共服务部		
申请(专利权)人(译)	美利坚合众国为代表局局长，DEPT.健康和人类服务		
当前申请(专利权)人(译)	美利坚合众国为代表局局长，DEPT.健康和人类服务		
[标]发明人	RESTIFO NICHOLAS P CASSARD LYDIE YU ZHIYA ROSENBERG STEVEN A		
发明人	RESTIFO, NICHOLAS P. CASSARD, LYDIE YU, ZHIYA ROSENBERG, STEVEN A.		
IPC分类号	A61K35/12 C12N5/08 C07K14/725 C07K16/18 C07H21/04 C12N15/63 G01N33/53 A61P35/04		
CPC分类号	A61K38/00 C07K14/7051 C12N15/85 C07K16/30 G01N33/57492 C07K14/70503 C12N15/86 A61P35/04		
优先权	60/884732 2007-01-12 US 60/885724 2007-01-19 US		
其他公开文献	US8216565		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明提供了人细胞，特别是人T细胞，其包含对癌抗原gp100具有抗原特异性的鼠T细胞受体 (TCR)。对gp100 (SEQ ID NO: 1) 的氨基酸154-162具有抗原特异性的分离或纯化的TCR，以及相关多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体或抗原结合还提供了其片段，缀合物和药物组合物。本发明进一步提供了检测宿主中癌症存在的方法和/或治疗或预防宿主癌症的方法，包括使用本文所述的本发明材料。

